Viveve Medical (VIVE) 10-K 16 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 10, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		18,341,294
Entity Public Float			$1,093,250
Amendment Flag	FALSE
Entity Central Index Key	879682
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$895,000	$430,000
Accounts receivable	6,000
Inventory	131,000	228,000
Prepaid expenses and other current assets	923,000	308,000
Total current assets	1,955,000	966,000
Property and equipment, net	187,000	128,000
Other assets	156,000	44,000
Total assets	2,298,000	1,138,000
Current liabilities:
Accounts payable	416,000	967,000
Accrued liabilities	223,000	516,000
Note payable	2,500,000	1,463,000
Related party convertible bridge notes		4,875,000
Total current liabilities	3,139,000	7,821,000
Preferred stock warrant liabilities		624,000
Total liabilities	3,139,000	8,445,000
Commitments and contingences (Note 8)
Stockholders’ equity (deficit):
Convertible Preferred Stock	0	0
Common stock, $0.001 par value; 612,000,000 shares authorized as of December 31, 2013; 0 and 6,555,305 shares issued and outstanding as of December 31, 2014 and 2013, respectively		7,000
Common stock and paid-in capital, no par value; unlimited shares authorized as of December 31 2014; 18,341,294 and 0 shares issued and outstanding as of December 31, 2014 and 2013, respectively	35,244,000
Additional paid-in capital		22,396,000
Accumulated deficit	-36,085,000	-29,905,000
Total stockholders’ equity (deficit)	-841,000	-7,307,000
Total liabilities and stockholders’ equity (deficit)	2,298,000	1,138,000
Series A Preferred Stock [Member]
Stockholders’ equity (deficit):
Convertible Preferred Stock		24,000
Series B Preferred Stock [Member]
Stockholders’ equity (deficit):
Convertible Preferred Stock		$171,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Preferred Stock, par value (in Dollars per share)	$0	$0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0	$0.00
Common stock, shares authorized		612,000,000
Common stock, shares issued	18,341,294	6,555,305
Common stock, shares outstanding	18,341,294	6,555,305
Series A Preferred Stock [Member]
Preferred Stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	0	24,543,626
Preferred stock, shares issued	0	23,863,302
Preferred stock, shares outstanding	0	23,863,302
Preferred stock, liquidation value (in Dollars)		$14,556,614
Series B Preferred Stock [Member]
Preferred Stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	0	227,000,000
Preferred stock, shares issued	0	171,199,348
Preferred stock, shares outstanding	0	171,199,348
Preferred stock, liquidation value (in Dollars)		$8,559,967

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenue	$90	$152
Cost of revenue	50	182
Gross profit	40	-30
Research and development	1,426	772
Selling, general and administrative	4,276	3,129
Total operating expenses	5,702	3,901
Loss from operations	-5,662	-3,931
Interest expense, net	-567	-447
Other income (expense), net	49	61
Net loss	($6,180)	($4,317)
Net loss per share:
Basic and diluted (in Dollars per share)	($1.27)	($81.81)
Weighted average shares used in computing net loss per common share
Basic and diluted (in Shares)	4,865,546	52,768

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Including Additional Paid in Capital [Member]	Common Stock Including Additional Paid in Capital [Member]	Common Stock Including Additional Paid in Capital [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
	Preferred Stock [Member]	Preferred Stock [Member]	USD ($)	Extinguishment of Related Party Debt [Member]	Rights to Shares [Member]	USD ($)	USD ($)	USD ($)	USD ($)
	USD ($)	USD ($)
Balances at Dec. 31, 2012	$24,000	$171,000	$7,000				$22,309,000	($25,888,000)	($3,077,000)
Balances (in Shares) at Dec. 31, 2012	23,863,302	171,199,348	6,555,305
Stock-based compensation expense							87,000		87,000
Comprehensive and net loss								-4,317,000	-4,317,000
Balances at Dec. 31, 2013	24,000	171,000	7,000				22,396,000	-29,905,000	-7,307,000
Balances (in Shares) at Dec. 31, 2013	23,863,302	171,199,348	6,555,305
Extinguishment of related party convertible notes and related accrued interest							5,397,000		5,397,000
Extinguishment of warrants							572,000		572,000
Stock exchange pursuant to Merger Agreement	-24,000	-171,000	-7,000			28,551,000	-28,365,000		-16,000
Stock exchange pursuant to Merger Agreement (in Shares)	-23,863,302	-171,199,348	-6,555,305			3,743,282
Issuance of common stock (in Shares)				943,596	1,179,461
PLC common stock assumed in connection with Merger (in Shares)						2,024,217
Private placement offering, net of issuance costs						4,204,000			4,204,000
Private placement offering, net of issuance costs (in Shares)						8,389,187
Conversion of outstanding amount of principal and interest of certain bridge notes in connection with private placement offering						1,546,000			1,546,000
Conversion of outstanding amount of principal and interest of certain bridge notes in connection with private placement offering (in Shares)						2,916,380
Issuance of warrant in connection with note payable						622,000			622,000
Issuance of warrants to vendors and service providers						137,000			137,000
Stock-based compensation expense						184,000			184,000
Exercise of stock option (in Shares)						160			160
Cancellation of shares in exchange for rights to shares (in Shares)						-854,989
Comprehensive and net loss								-6,180,000	-6,180,000
Balances at Dec. 31, 2014						$35,244,000		($36,085,000)	($841,000)
Balances (in Shares) at Dec. 31, 2014						18,341,294

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($6,180,000)	($4,317,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	56,000	66,000
Stock-based compensation expense	184,000	87,000
Issuance of warrants to vendors and service providers	137,000
Revaluation of fair value of warrant liability	-52,000	-62,000
Noncash interest expense	418,000	306,000
Loss on disposal of property and equipment	2,000
Changes in assets and liabilities:
Accounts receivable	-6,000	1,000
Inventory	97,000	71,000
Prepaid expenses and other current assets	-41,000	-243,000
Other noncurrent assets	-112,000	14,000
Accounts payable	-551,000	482,000
Accrued liabilities	57,000	-160,000
Net cash used in operating activities	-5,991,000	-3,755,000
Cash flows from investing activities:
Purchase of property and equipment	-117,000	-4,000
Net cash used in investing activities	-117,000	-4,000
Cash flows from financing activities:
Net cash proceeds from issuance of common stock in connection with private placement offering	4,204,000
Proceeds from notes payable	2,500,000
Proceeds from related party convertible bridge notes	1,500,000	3,875,000
Repayments of notes payable	-1,631,000	-135,000
Net cash provided by financing activities	6,573,000	3,740,000
Net increase (decrease) in cash and cash equivalents	465,000	-19,000
Cash and cash equivalents - beginning of period	430,000	449,000
Cash and cash equivalents - end of period	895,000	430,000
Supplemental disclosure:
Cash paid for interest	149,000	141,000
Cash paid for income taxes	1,000	1,000
Supplemental disclosure of cash flow information as of end of period:
Conversion of certain bridge notes and related accrued interest in connection with private placement offering	1,546,000
Extinguishment of convertible notes debt and related related accrued interest pursuant to Merger Agreement	5,397,000
Extinguishment of warrants pursuant to Merger Agreement	572,000
Issuance of warrants in connection with note payable	622,000
Payable to non-accredited investors in connection with Merger Agreement	16,000
Transfer of equipment between inventory and property and equipment		$61,000

Note_1_The_Company_and_Basis_o

Note 1 - The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1.        The Company and Basis of Presentation
	On September 23, 2014, PLC Systems, Inc., a Yukon Territory corporation (“PLC”) completed an Agreement and Plan of Merger (“Merger Agreement” or “Merger”) with Viveve®, Inc., a Delaware corporation (“Viveve”). As of that date, Viveve operates as a wholly-owned subsidiary of PLC and PLC is known as Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”). Viveve Medical competes in the women’s health market with a focus on the Viveve System™ to improve women’s overall sexual well-being and quality of life, retained all its personnel and continues to be headquartered in Sunnyvale, California.
	At the effective time of the Merger, PLC divested its ownership of its former operating subsidiaries, PLC Medical Systems, Inc. and PLC Systemas Medicos Internacionais, which will operate as independent entities going forward under new ownership.
	In preparation for the stock exchange pursuant to the Merger, Viveve convertible bridge notes in the aggregate amount of $4,875,000 and related accrued interest of approximately $522,000 were extinguished.
	Additionally, Viveve warrant liabilities of approximately $572,000 were extinguished in preparation of the stock exchange pursuant to the Merger.
	Pursuant to the Merger Agreement, all shares of capital stock (including common and preferred stock) of Viveve were converted into 3,743,282 shares of the Company's common stock which represented approximately 62% of the issued and outstanding shares of common stock of the Company on a fully diluted basis. In addition, non-accredited investors were entitled to receive approximately $16,000 upon closing. Upon the closing of the Merger, the Company issued an additional 943,596 shares of common stock upon the automatic conversion of a warrant issued in exchange for the cancellation of related party convertible bridge notes.
	The acquisition was accounted for as a reverse merger and recapitalization effected by a share exchange. Viveve is considered the acquirer for accounting and financial reporting purposes. The assets and liabilities of the acquired entity have been brought forward at their book value and no goodwill has been recognized.
	Concurrent with the Merger, Viveve Medical completed a private placement for total gross proceeds of approximately $6 million (including approximately $1.5 million of convertible bridge note conversion). As a result, Viveve Medical issued 11,305,567 shares of common stock and 5-year warrants to purchase up to 940,189 shares of common stock at an exercise price of $0.53 per share.
	The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and has an accumulated deficit of $36,085,000 as of December 31, 2014. Management expects operating losses to continue through the foreseeable future. The Company's ability to transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The Company has not generated significant revenues and has funded its operating losses through the sale of preferred and common stock and the issuance of debt. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the industry. These risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability. Management of the Company intends to raise additional funds through the issuance of equity securities. There can be no assurance that such financing will be available or on terms which are favorable to the Company. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The condolidated financial statements do not contain any adjustments that might result from the outcome of this uncertainty.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2.         Summary of Significant Accounting Policies
	Financial Statement Presentation
	The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity of three months or less, at the time of purchase, to be cash equivalents. The Company’s cash and cash equivalents are deposited in demand accounts primarily at one financial institution. Deposits in this institution may, from time to time, exceed the federally insured amounts.
	Concentration of Credit Risk and Other Risks and Uncertainties
	To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows.
	The Company’s products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse impact on the Company’s financial results, financial position and future cash flows.
	The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products.
	During the year ended December 31, 2014, two customers accounted for 91% of the Company’s revenue. During the year ended December 31, 2013, three customers accounted for 100% of the Company’s revenue.
	Inventory
	Inventory is stated at the lower of cost or market. Cost is determined on an actual cost basis on a first-in, first-out method. Lower of cost or market is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory. Excess and obsolete inventory is charged to cost of revenue and a new lower-cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
	As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five years. The amortization of the demos is charged to selling, general and administrative expense and the demos are included in the medical equipment line of the property and equipment balance on the consolidated balance sheet as of December 31, 2014 and 2013.
	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight line method over their estimated useful lives of three to seven years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful lives or the life of the lease. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date.
	Preferred Stock Warrants
	Freestanding warrants and other similar instruments related to shares that are redeemable are classified as liabilities on the balance sheet. The warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense), net. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the preferred stock warrants.
	Revenue Recognition
	The Company recognizes revenue from the sale of its products, the Viveve® System, single-use treatment tips and ancillary consumables. Revenue is recognized upon delivery, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of Viveve’s products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance outside the U.S. and currently sells the Viveve System in Canada, Hong Kong and Japan.
	The Company does not provide its customers with a contractual right of return.
	Product Warranty
	The Company’s products are generally subject to a one year warranty, which provides for the repair, rework or replacement of products (at its option) that fail to perform within stated specification. The Company has assessed the historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual going forward.
	Shipping and Handling Costs
	The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue.
	Advertising Costs
	Advertising costs are charged to general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2014 and 2013.
	Research and Development
	Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.
	Income Taxes
	The Company account for income taxes in accordance with Accounting Standards Codification (“ASC”) 740, Income Taxes (“ASC 740”), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax asset will not be realized. We evaluate annually the realizability of our deferred tax assets by assessing our valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include our forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. As of December 31, 2014 and 2013, the Company has recorded a full valuation allowance for our deferred tax assets based on our historical loss and the uncertainty regarding our ability to project future taxable income. In future periods if we are able to generate income we may reduce or eliminate the valuation allowance.
	Accounting for Uncertainty in Income Taxes
	The Company accounts for uncertain tax positions in accordance with ASC 740.  ASC 740 seeks to reduce the diversity in practice associated with certain aspects of measurement and recognition in accounting for income taxes. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with our accounting policy, we recognize accrued interests and penalties related to unrecognized tax benefits as a component of income tax.
	Accounting for Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation (“ASC 718”) which establishes accounting for stock-based awards exchanged for employee services. Accordingly, share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award.
	We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock.
	Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
	Comprehensive Loss
	Comprehensive loss represents the changes in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2014 and 2013, the Company’s comprehensive loss is the same as its net loss.
	Net Loss per Share
	The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, convertible preferred stock, warrants to purchase convertible preferred stock and common stock, stock options and rights to common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Potential common shares will always be anti-dilutive for periods in which the Company has reported a net loss. Diluted net loss per share is the same as basic net loss per share for the years ended December 31, 2014 and 2013.
	For the years ended December 31, 2014 and 2013, the following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive.
		Year Ended
		December 31,
		2014		2013
	Convertible preferred stock		-		195,062,650
	Warrants to purchase convertible preferred stock		-		16,680,324
	Stock options to purchase common stock		2,291,783		363,413
	Warrants to purchase common stock		1,793,887		-
	Rights to common stock		566,038		-
	Recently Issued and Adopted Accounting Standards
	In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual and interim periods beginning after December 15, 2016. We are currently evaluating the impact that this standard will have on our consolidated financial statements.
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved After a Requisite Service Period” (“ASU 2014-12”). Companies commonly issue share-based payment awards that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. The performance target should not be reflected in estimating the grant date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. ASU 2014-12 will be effective for the Company’s fiscal years beginning fiscal 2016 and interim reporting periods within that year, using either the retrospective or prospective transition method. Early adoption is permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements.
	In June 2014, the FASB issued ASU 2014-10, “Development Stage Entities (Topic 915):  Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in topic 810, Consolidation” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. ASU 2014-10 also eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. The amendments in ASU 2014-10 will be effective retrospectively except for the clarification to Topic 275, which shall be applied prospectively for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. We elected to early adopt the provisions of ASU 2014-10 in the second quarter of 2014.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements and disclosures.

Note_3_Fair_Value_Measurements

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	3.        Fair Value Measurements
	The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value.
		Level 1	Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult.
		Level 2	Pricing is provided by third party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors.
		Level 3	Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.
	The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2014 and 2013, approximate fair value because of the short maturity of these instruments. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair value.
	The Company does not have any Level 1, Level 2 or Level 3 financial assets. Additionally, the Company does not have any Level 1 or Level 2 liabilities. The Company’s Level 3 liability consists of convertible preferred stock warrant liabilities as of December 31, 2013. The valuation of the warrant liabilities is discussed in Note 10. The warrants were extinguished in connection with the Merger.
	For the year ended December 31, 2014, the Company did not have any transfers between Level 1, Level 2 and Level 3.
	There were no financial instruments that were measured at fair value on a recurring basis as of December 31, 2014. The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis as of December 31, 2013 by level within the fair value hierarchy (in thousands):
			Assets and Liabilities at Fair Value as of December 31, 2013
			Quoted prices in active markets for identical assets			Significant				Significant unobservable
						other observable inputs				inputs
			Level 1			Level 2				Level 3		Total
	Assets
			$	-		$	-			$	-	$	-
	Total assets		$	-		$	-			$	-	$	-
	Liabilities
	Preferred stock warrant liabilities		$	-		$	-			$	624	$	624
	Total liabilities		$	-		$	-			$	624	$	624
	The change in the fair value of the preferred stock warrant liabilities is summarized below (in thousands):
	Fair value as of December 31, 2012		$	686
	Change in fair value recorded in other income (expense), net			(62	)
	Fair value as of December 31, 2013			624
	Change in fair value recorded in other income (expense), net			(52	)
	Extinguishment of warrant liabilities pursuant to the Merger Agreement			(572	)
	Fair value as of December 31, 2014		$	-
	The following table presents quantitative information about the inputs and valuation methodologies used for our fair value measurements classified in Level 3 of the fair value hierarchy as of December 31, 2013.
		Fair Value as of
		31-Dec-13			Valuation	Unobservable	Range
		(in thousands)			Techniques	Input	(Weighted-Average)
	Preferred stock warrant liabilities	$	624		Black-Scholes	Preferred series
					option pricing	prices		$0.04	-	$0.44	($0.06)
					model
						Volatility		70.60%	-	84.20%	-76%
	There were no changes in valuation technique from prior periods.

Note_4_Property_and_Equipment_

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, Net
	Property and equipment, net, consisted of the following as of December 31, 2014 and 2013 (in thousands):
		Life		December 31,
		(in years)		2014			2013
	Medical equipment		5	$	367		$	277
	Computer equipment		3		39			32
	Furniture and fixtures		7		13			13
					419			322
	Less: Accumulated depreciation and amortization				(232	)		(194	)
	Property and equipment, net			$	187		$	128
	Depreciation and amortization expense for the years ended December 31, 2014 and 2013 was $56,000 and $66,000, respectively.

Note_5_Accrued_Liabilities

Note 5 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5.         Accrued Liabilities
	Accrued liabilities consisted of the following as of December 31, 2014 and 2013 (in thousands):
		December 31,
		2014		2013
	Accrued professional fees	$	117	$	15
	Accrued vacation		86		81
	Accrued interest		-		237
	Accrued loan balloon payment		-		76
	Accrued loan restructuring fees		-		27
	Accrued severence pay		-		59
	Other accruals		20		21
	Total accrued liabilities	$	223	$	516

Note_6_Note_Payable

Note 6 - Note Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	6.       Note Payable
	In April 2012, the Company entered into a loan and security agreement for up to $2,135,159 in term loans that were used to pay off an existing loan with a financial institution. The full amount was drawn down in April 2012. In connection with the agreement, the Company issued a warrant to the lender to purchase a total of 73,770 shares of the Company’s Series A convertible preferred stock at $0.61 per share (see Note 10). The borrowings were repayable in interest only payments until May 1, 2012 and then 30 equal installments of principal and interest at a rate of 9.5% per annum. An additional 4% of the principal or approximately $85,000 was due as the final payment at the end of the loan term. The Company recorded $9,000 and $35,000 as additional interest expense during the years ended December 31, 2014 and 2013, respectively, related to the $85,000 payment. The Company had been accruing the balance of the $85,000 cash payment over the term of the loan using the effective interest rate method. As of December 31, 2014 and 2013, $0 and $76,000, respectively, was recorded in accrued liabilities on the consolidated balance sheets relating to this payment. All borrowings under the agreement were collateralized by substantially all of the Company’s assets, including intellectual property. As of December 31, 2014 and 2013, the note payable had an outstanding balance of $0 and $1,463,000, respectively. The term loan had a maturity date of October 1, 2014 and was repaid on that date as discussed below.
	In February 2013, the Company and the lender amended the loan and security agreement to defer up to 3 months of principal payments contingent upon the receipt of bridge loan proceeds in increments of $500,000, up to $1,500,000 on or before April 30, 2013, beginning March 1, 2013. This amendment also included a $15,000 restructuring fee that would be due upon the maturity date of the loan.
	In May 2013, the Company and the lender amended the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more, on or before September 30, 2013. The principal payments were to be deferred and payable on August 1, 2013. This amendment also included a $10,000 restructuring fee that would be due upon the maturity date of the loan.
	In July 2013, the Company and the lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more, on or before August 28, 2013, and an additional month deferral provided a 2013 equity event was completed resulting in net cash proceeds of not less than $10 million from the sale of the Company’s equity securities consummated by September 27, 2013. Principal payments would be deferred and payable on October 1, 2013, provided both of these conditions were met. This amendment also included a $10,000 restructuring fee that would be due upon the maturity date of the loan.
	In September 2013, the Company and the lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before August 28, 2013 and another $500,000 or more on or before October 28, 2013. Principal payments would be deferred until December 1, 2013. This amendment also included a $10,000 restructuring fee that would be due upon the maturity date of the loan.
	In November 2013, the Company and the lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before December 27, 2013 and upon the consummation of a 2014 equity event requiring the receipt of not less than $7 million in net cash proceeds by no later than January 24, 2014. Principal payments would be deferred until February 1, 2014. This amendment also included a $10,000 restructuring fee that would be due upon the maturity date of the loan.
	In January 2014, the Company and the lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before February 25, 2014 and consummation of an equity event by April 25, 2014. This amendment included an additional $5,000 restructuring fee for each month principal payments were deferred beginning February 1, 2014 through April 1, 2014, provided restructuring fees in this amendment would not exceed $15,000 in total. The restructuring fees were due upon the maturity date of the loan.
	In February 2014, the Company and the lender agreed to further amend the loan and security agreement to defer an additional 2 months of principal payments contingent upon the receipt of bridge loan proceeds of $500,000 or more on or before April 25, 2014 and consummation of an equity event by June 27, 2014. This amendment included an additional $5,000 restructuring fee for each month principal payments were deferred beginning March 1, 2014 through June 1, 2014, provided restructuring fees in this amendment shall not exceed $20,000. This amendment also amended the January 2014 restructuring fee such that the January 2014 restructuring fee would not exceed $5,000 in total and would be due upon the maturity date of the loan.
	In June 2014, the Company and the lender agreed to further amend the loan and security agreement such that the remaining 3 months of principal payments would be deferred until the maturity date of the term loan when all unpaid principal and interest would be immediately due. This amendment also included an additional $5,000 restructuring fee for each month principal payments were deferred beginning July 1, 2014 through September 1, 2014, provided restructuring fees in this amendment were not to exceed $15,000 in total. The restructuring fees were due upon the maturity date of the loan.
	In September 2014, the lender agreed to reduce the total restructuring fees to $47,500. The Company recorded $20,000, net of the reduction in fees, and $27,000 as additional interest expense during the years ended December 31, 2014 and 2013, respectively, related to these restructuring fees. The Company has been accruing the balance of the cash restructuring payment over the term of the loan using the effective interest rate method. As of December 31, 2014 and 2013, $0 and $27,000, respectively, was recorded as an accrued liability on the consolidated balance sheets relating to this restructuring payment.
	On September 30, 2014, the Company entered into a Loan and Security Agreement pursuant to which it received a term loan in the amount of $5 million, which will be funded in three tranches. The first tranche of $2.5 million was provided to the Company on October 1, 2014. The proceeds from the first tranche were used to repay the existing loan of $1,631,000 with a financial institution and to fund operations. Before the second and the third tranches of the term loan will be funded, the Company must meet certain enrollment milestones and achieve certain positive results relating to its OUS Clinical Trial, among other things. The borrowings are repayable in interest only payments until November 1, 2015 and then 30 equal installments of principal and interest at a rate of 5.25% per annum. All borrowings under the agreement are collateralized by substantially all of the Company’s assets, including intellectual property. The loan agreement requires that the Company comply with certain financial and other covenants for borrowings to be permitted. In connection with the loan agreement, the Company issued a 10-year warrant to the lender for the purchase of 471,698 shares of the Company’s common stock at $0.53 per share (see Note 9). As of December 31, 2014, the note payable had an outstanding balance of $2,500,000, that is recorded as a current liability on the consolidated balance sheets and the Company was in compliance with all covenants of the loan agreement.
	The loan and security agreements with both financial institutions contain a material adverse change clause, as defined in the agreement, which would result in an event of default if the lender deems a material adverse change to have occurred to the Company’s business. The continuing liquidity issues the Company faces could be construed by the note holder as a material adverse change which could trigger an acceleration of all of the outstanding debt. As such, the Company has classified all of its outstanding debt balance as a current liability as of December 31, 2014 and 2013.
	As of December 31, 2014, future minimum payments under the note payable are as follows (in thousands):
	Year Ending December 31,
	2015	$	293
	2016		1,095
	2017		1,045
	2018		337
	Total Payments		2,770
	Less: Amount representing interest		(270	)
	Present value of obligations		2,500
	Less: Notes payable, current portion		2,500
	Note payable, noncurrent portion	$	-

Note_7_Related_Party_Convertib

Note 7 - Related Party Convertible Bridge Notes (Related Party Convertible Bridge Notes [Member])	12 Months Ended
	Dec. 31, 2014
Related Party Convertible Bridge Notes [Member]
Note 7 - Related Party Convertible Bridge Notes [Line Items]
Long-term Debt [Text Block]	7.        Related Party Convertible Bridge Notes
	In November 2012, the Company issued $1,000,000 in convertible promissory notes to related parties. The notes accrue interest at 8% per annum and mature at the earlier of i) the date upon which the majority note holders demand repayment after May 15, 2013 or ii) the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000. As of December 31, 2014 and 2013, the outstanding principal balance was $0 and $1,000,000. Because the holders had the ability to demand repayment after May 15, 2013, the Company classified all of the outstanding debt balance and related accrued interest of $89,000 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished.
	On February 13, 2013, the Company entered into a note purchase agreement (“2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $1,500,000 in the aggregate, of which $1,000,000 was issued. These notes were intended as bridge financing to a planned alternative public offering in the second quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after August 13, 2013 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes and the November 2012 notes. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 80% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of August 13, 2013. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 80% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. In April 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. On June 3, 2013, the Company entered into an amendment to the 2013 Note Purchase Agreement to increase the total amount of the convertible promissory notes up to $2,000,000 in the aggregate if issued before June 30, 2013. In June 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. On August 7, 2013, the Company entered into an amendment to the 2013 Note Purchase Agreement to increase the total amount of the convertible promissory notes up to $2,500,000 in the aggregate if issued before August 28, 2013. In August 2013, the Company completed another closing of the 2013 Note Purchase Agreement for $500,000. As of December 31, 2014 and 2013, the outstanding principal balance was $0 and $2,500,000. Because the holders had the ability to demand repayment after August 13, 2013, the Company classified all of the outstanding debt balance and related accrued interest of $130,000 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished.
	On September 27, 2013, the Company entered into a note purchase agreement (“September 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $500,000 in the aggregate. These notes were intended as bridge financing to a planned APO in the third quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of December 31, 2014 and 2013, the outstanding principal balance was $0 and $500,000. Because the holders had the ability to demand repayment after March 31, 2014, the Company classified all of the outstanding debt balance and related accrued interest of $10,000 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished.
	On November 12, 2013, the Company entered into a note purchase agreement (“November 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $500,000 in the aggregate. These notes were intended as bridge financing to a planned APO in the fourth quarter of 2013. The notes accrue interest at 8% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of December 31, 2014 and 2013, the outstanding principal balance was $0 and $500,000. Because the holders had the ability to demand repayment after March 31, 2014, the Company classified all of the outstanding debt balance and related accrued interest of $5,000 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished.
	On December 27, 2013, the Company entered into a note purchase agreement (“December 2013 Note Purchase Agreement”) with related parties to which it was authorized to issue and sell convertible promissory notes up to $375,000 in the aggregate. These notes were intended as bridge financing to a planned APO in the first quarter of 2014. The notes accrue interest at 9% per annum and mature at the earlier of the date upon which the majority note holders demand repayment after March 31, 2014 or the date of the closing of a qualified financing in which the Company issues common or preferred stock for gross proceeds of not less than $5,000,000 excluding the conversion of these notes, the November 2012 notes and the 2013 Note Purchase Agreement. The notes convert into the number of shares equal to the principal and unpaid accrued interest divided by the conversion price, which is defined as 70% of the purchase price in the qualified financing. If the Company does not execute a qualified financing, the holders may elect conversion of the notes prior to the maturity date of March 31, 2014. Under the elective conversion, the notes convert into the number of the next equity financing shares or shares of Series B convertible preferred stock that are equal to the principal and the unpaid accrued interest divided by the conversion price. The conversion price is defined as 70% of the price paid by the investors in the next equity financing series or $0.05, if the notes are converted into the Series B convertible preferred stock. As of December 31, 2014 and 2013, the outstanding principal balance was $0 and $375,000. Because the holders had the ability to demand repayment after March 31, 2014, the Company classified all of the outstanding debt balance and related accrued interest of $1,000 as a current liability as of December 31, 2013. In connection with the Merger, these convertible promissory notes were extinguished.
	On March 5, 2014, the Company entered into a note purchase agreement in which it was authorized to issue and sell up to $1,250,000 in aggregate principal amount of convertible promissory notes of which $200,000 was issued. In May 2014, the Company completed another sale of convertible promissory notes in the aggregate principal amount of $1,050,000. The notes accrued interest at 9% per annum and converted into common stock in connection with the private placement.
	On July 7, 2014, the Company entered into a note purchase agreement in which it was authorized to issue convertible promissory notes up to $250,000 in the aggregate. The notes accrue interest at 9% per annum and converted into common stock in connection with the private placement.
	Pursuant to the Company’s amendment to the note purchase agreement dated November 20, 2012, effective February 13, 2013, the above notes payable would be redeemable upon a change of control of the Company at an amount equal to 300% of the outstanding principal amount and accrued and unpaid interest on the notes as of the time of a change of control. A change of control will occur in the event the Company enters into a transaction where the holders of the voting securities no longer own a majority of the total outstanding voting securities once the transaction is completed or a disposition of substantially all assets occurs. The sale of stock for capital raising purposes or an alternative public offering involving a reverse merger into a public shell company for capital raising purposes is excluded from the Company’s definition of a change of control. The Company has determined that the value of this provision is not material and as such did not record a liability on the Company’s consolidated financial statements as of December 31, 2013. All of these notes were extinguished as part of the Merger Agreement.

Note_8_Commitments_and_Conting

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8.         Commitments and Contingencies
	Operating Lease
	In January 2012, the Company entered into a lease agreement for office and laboratory facilities. The lease commenced in March 2012 and will terminate in February 2015. Rent expense for the years ended December 31, 2014 and 2013 was $171,000 and $171,000, respectively.
	As of December 31, 2014, future minimum payments under the lease are as follows (in thousands):
	Year Ending December 31,
	2015	$	31
	Total minimum lease payments	$	31
	In January 2015, the Company entered into an amendment to the operating lease agreement (see Note 15).
	Indemnification Agreements
	The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not breached the agreement and/or the loss is not attributable to the indemnified party’s negligence or willful malfeasance. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal.
	Contingencies
	From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.

Note_9_Common_Stock

Note 9 - Common Stock	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9.        Common Stock
	In connection with the Merger, all shares of Viveve Series A convertible preferred stock and Series B convertible preferred stock were converted to common stock and the Company exchanged shares of common stock with the former stockholders of Viveve. The total common shares issued for these transactions was 3,743,282 shares based on the exchange ratio of 0.0080497.
	In connection with the proposed Merger, on May 9, 2014, Viveve issued to GBS Venture Partners Limited (“GBS”), a convertible debenture holder, a warrant to purchase shares of our common stock equal to approximately 5% of the outstanding shares of common stock on a post-Merger basis in consideration for the cancellation of convertible promissory notes in the aggregate principal amount of $1,750,000 and accrued interest of approximately $211,000 held by GBS. As part of the closing of the Merger, the Company issued 943,596 shares of common stock to GBS upon the automatic exercise of the warrant.
	Concurrent with the Merger, the Company completed a separate private placement of 11,305,567 shares of our common stock, together with warrants for the purchase of 940,189 shares of common stock, for gross proceeds of approximately $6,000,000, which included the conversion of $1,546,000 of convertible promissory notes and related accrued interest. The price per unit was $0.53.
	In conjunction with the 2014 private placement, the Company entered into a Right to Shares Agreement with certain investors. Pursuant to this agreement, 854,989 shares of common stock purchased by the investors were cancelled. The Company is obligated to issue, and the investors have the right to up to 956,354 shares of the Company’s common stock, which includes 101,365 shares that were not issued in the private placement due to beneficial ownership limitations. No additional consideration will be paid upon the issuance of the shares and the subscription amount has been paid in full by the investors and is non-refundable. The Company is obligated to deliver the shares to the investors within 3 days of the investors’ request for the share issuance. If the Company fails to deliver the shares within 3 days of the request, under certain circumstances defined in the Right to Shares Agreement, the Company may be obligated to reimburse the investors in cash for losses that the investors incur as a result of not having access to the shares (the “Buy-In Shares”). In December 2014, certain investors exercised their right to shares and the Company issued 390,316 shares of common stock. As of December 31, 2014, the Company has reserved, but not issued 566,038 shares of common stock pursuant to the Right to Shares Agreement.
	In conjunction with a Warrant-Equity Exchange Agreement in May 2014, the Company entered into a Right to Shares Agreement with an investor. Pursuant to the Right to Shares Agreement, in lieu of issuing 432,479 shares of common stock under the Warrant-Equity Exchange Agreement, the Company granted a right to receive up to 432,479 shares of its common stock. In December, 2014, the right to receive shares of common stock was exercised and 432,479 shares of common stock were issued. No additional consideration was paid upon the exercise of this right and no additional shares are issuable under this Right to Shares Agreement.
	In conjunction with 2013 private placements, the Company entered into Right to Shares Agreements with certain investors. Pursuant to the Right to Shares Agreements, in lieu of issuing shares of common stock, the Company granted rights to receive shares of its common stock. In December 2014, rights to receive 356,666 shares of common stock were exercised and 356,666 shares of common stock were issued. No additional shares are issuable under this Right to Shares Agreement.
	The Company assessed the provisions of the Buy-In Share features of the Right to Shares Agreements as an embedded derivative and has concluded that the feature meets the definition of a derivative and is not clearly and closely related to the Rights to Shares equity host agreement. The Buy-In Shares feature has been bifurcated from the Rights to Shares agreement and accounted for separately. The value of this feature was nominal as of the issuance date and December 31, 2014.
	Warrants for Common Stock
	In connection with the private placement, the Company issued warrants to purchase a total of 940,189 shares of common stock at an exercise price of $0.53 per share. The warrants have a contractual life of five years and are exercisable immediately in whole or in part, on or before five years from the issuance date.
	In connection with the Loan and Security Agreement entered into on September 30, 2014, the Company issued a warrant to purchase a total of 471,698 shares of common stock at an exercise price of $0.53 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrant on the date of issuance to be $622,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 77%, risk free interest rate of 2.5% and a contractual life of ten years. The warrant will expire on September 30, 2024. The fair value of the warrant was recorded as debt issuance costs, included in prepaid expenses and other current assets on the consolidated balance sheets and will be amortized to interest expense over the loan term. During the year ended December 31, 2014, the Company recorded $48,000 of interest expense relating to the debt issuance costs. As of December 31, 2014, the remaining unamortized debt issuance costs were $574,000.
	In the fourth quarter of 2014, the Company issued common stock warrants to various vendors and nonemployee contractors to purchase a total of 382,000 shares of common stock at an exercise price of $0.53 per share. The warrants have a contractual life of five years and are exercisable either immediately upon grant or in some cases upon achieving certain milestones or vesting terms. The Company determined the fair value of the warrants using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 61.3%, risk free interest rate of 1.55% to 1.65% and a contractual life of five years. The fair value of the warrants were recorded as professional consulting fees or clinical costs, which are included in selling, general and administrative and research and development expenses in the consolidated statements of operations for the year ended December 31, 2014, depending on the nature of the services provided. Stock-based compensation expense related to these warrants is recognized as the warrants are earned and was $137,000 for the year ended December 31, 2014.
	As of December 31, 2014, all of these warrants remain outstanding.

Note_10_Convertible_Preferred_

Note 10 - Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	10.       Convertible Preferred Stock
	As part of the Merger Agreement, all shares of the Series A convertible preferred stock and Series B convertible preferred stock converted to common stock, pursuant to the conversion rights.
	The holders of preferred stock had various rights and preferences as follows:
	Dividends
	The preferred stockholders were entitled to receive, when and as declared by the Board of Directors, out of funds legally available, cash dividends in the amount of $0.0488 and $0.004, respectively, per share, per year for each share of Series A and Series B outstanding in preference and priority to any declaration or payment of any distribution on common stock in such calendar year. These dividends are noncumulative. No distributions could be made to common stock unless all declared dividends on preferred stock have been paid or set aside for payment. No dividends have been declared to date.
	Liquidation
	Upon liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of the Series A and Series B were entitled to receive an amount per share equal to the original issuance price for the preferred stock (as adjusted for any stock dividends, stock splits or recapitalization and similar events), plus all declared and unpaid dividends thereon to the date fixed for such distribution. If upon the liquidation event, there were insufficient funds to permit the payment to stockholders of the full preferential amounts, then the entire assets and funds of the Company would be distributed ratably among the holders of preferred stock.
	Conversion
	At the option of the holder thereof, each share of preferred stock was convertible, at the option of the holder at any time after the date of issuance into fully paid and non-assessable shares of common stock as determined by dividing the applicable original issue price for such series by the conversion price for such series. The conversion price was $0.05 for Series A and Series B.
	Each share of preferred stock was to automatically be converted into shares of common stock at their respective conversion price immediately upon the earlier of (A) immediately prior to the closing of a firm commitment underwritten initial public offering pursuant to a registration statement under the Securities Act of 1933 covering the offering and sale of the Company’s common stock provided the aggregate gross proceeds to the Company and/or selling stockholders was not less than $30,000,000 prior to underwriters’ commissions and expenses, or (B) upon receipt of a written request for conversion from the holders of a majority of the voting power of the outstanding shares of preferred stock.
	Voting
	Each holder of preferred stock was entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of preferred stock could be converted as of the record date. The holders of shares of the preferred stock were entitled to vote on all matters on which the common stock was entitled to vote. The holders of preferred stock, voting as a separate class, were entitled to elect two members of the Board of Directors. The holders of common stock, voting as a separate class, were entitled to elect one member of the Board of Directors. Any additional members of the Board of Directors were to be elected by the holders of common stock and preferred stock, voting together as a single class.
	Warrants for Convertible Preferred Stock
	In connection with the loan and security agreement entered into in December 2008, the Company issued a warrant to purchase a total of 196,721 shares of Series A at an exercise price of $0.61 per share. The warrant had a contractual life of ten years and was exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $54,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.7% and a contractual life of ten years. The warrant was to expire on December 2, 2018. The fair value of the warrant was recorded as a debt issuance cost in other assets and was amortized to interest expense over the draw down term of the loan. The entire amount of the warrant was amortized to interest expense in the year ended December 31, 2008. The fair value of the warrant was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $10,000 and $7,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In connection with the Series A offering in 2009, the Company issued warrants to purchase 245,900 shares of Series A for $0.61 per share in April 2009. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrants on the date of issuance to be $70,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.8% and a contractual life of ten years. The warrants were to expire on April 2, 2019. The fair value of the warrants was recorded as an equity issuance cost. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $12,000 and $9,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In connection with the loan and security agreement entered into in November 2010, the Company issued a warrant to purchase a total of 163,934 shares of Series A at an exercise price of $0.61 per share. The warrant had a contractual life of ten years and was exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $47,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 79%, risk free interest rate of 2.9% and a contractual life of ten years. The warrant was to expire on November 19, 2020. The fair value of the warrant was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrant was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $2,000 and $2,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In connection with the loan and security agreement entered into in April 2012, the Company issued a warrant to purchase a total of 73,770 shares of Series A at an exercise price of $0.61 per share. The warrant had a contractual life of ten years and was exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrant on the date of issuance to be $27,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 92%, risk free interest rate of 1.98% and a contractual life of ten years. The warrant was to expire on April 19, 2022. The fair value of the warrant was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrant was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $3,000 and $2,000 was recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In May 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 2,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $84,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 3.2% and a contractual life of ten years. The warrants were to expire on May 9, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $2,000 and $6,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In June 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 4,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $168,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 3.2% and a contractual life of ten years. The warrants were to expire on June 30, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $4,000 and $12,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In September 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 4,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $168,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.0% and a contractual life of ten years. The warrants were to expire on September 9, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $0 and $12,000 was recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In November 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 1,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $42,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.1% and a contractual life of ten years. The warrants were to expire on November 30, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $1,000 and $2,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In December 2011, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 1,000,000 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $41,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.8% and a contractual life of ten years. The warrants were to expire on December 19, 2021. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $1,000 and $2,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In January 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 910,445 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $37,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.8% and a contractual life of ten years. The warrants were to expire on January 31, 2022. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $4,000 and $2,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In February 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 738,535 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $31,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 1.98% and a contractual life of ten years. The warrants were to expire on February 27, 2022. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $3,000 and $1,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	In April 2012, in connection with the issuance of convertible promissory notes, the Company issued warrants to purchase 2,351,019 shares of Series B at an exercise price of $0.05 per share. The warrants had a contractual life of ten years and were exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the value of the warrants on the date of issuance to be $99,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 84%, risk free interest rate of 2.0% and a contractual life of ten years. The warrants were to expire on April 16, 2022. The fair value of the warrants was recorded as a debt discount and amortized to interest expense over the life of the loan. The fair value of the warrants was re-measured as of the date of the Merger, September 23, 2014, and December 31, 2013 and $9,000 and $5,000 were recorded to other income (expense), net, respectively, for the years ended December 31, 2014 and 2013. The warrants were extinguished in connection with the Merger.
	Convertible preferred stock warrants outstanding as of December 31, 2013 were as follows:
						Number of
						Shares
		Series				Outstanding		Fair Value
		Exercisable	Expiration	Exercise		Under		December 31,
	Issuance Date	for	Date	Price		Warrants		2013
	Dec-08	Series A	2-Dec-18	$	0.61		196,721	$	44,000
	Apr-09	Series A	2-Apr-19		0.61		245,900		58,000
	Nov-10	Series A	19-Nov-20		0.61		163,934		47,000
	May-11	Series B	6-May-21		0.05		2,000,000		54,000
	Jun-11	Series B	30-Jun-21		0.05		4,000,000		108,000
	Sep-11	Series B	9-Sep-21		0.05		4,000,000		108,000
	Nov-11	Series B	30-Nov-21		0.05		1,000,000		28,000
	Dec-11	Series B	19-Dec-21		0.05		1,000,000		28,000
	Jan-12	Series B	31-Jan-22		0.05		910,445		28,000
	Feb-12	Series B	28-Feb-22		0.05		738,535		23,000
	Apr-12	Series B	16-Apr-22		0.05		2,351,019		73,000
	Apr-12	Series A	19-Apr-22		0.61		73,770		25,000
							16,680,324	$	624,000

Note_11_Summary_of_Stock_Optio

Note 11 - Summary of Stock Options	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11.      Summary of Stock Options
	Stock Option Plans
	The Company has issued equity awards in the form of stock options from three employee benefit plans. The plans include the PLC 2005 Stock Incentive Plan (the “2005 Plan”), the Viveve Amended and Restated 2006 Stock Plan (the “2006 Plan”) and the PLC 2013 Stock Option and Incentive Plan (the “2013 Plan”).
	The 2005 Plan was adopted by PLC's Board of Directors and approved by its stockholders. 22,095 shares of common stock remain reserved for issuance under the 2005 Plan. The Company does not intend to grant further awards from the 2005 Plan, however, it will continue to administer the 2005 Plan until all outstanding awards are exercised, expire, terminate or are forfeited. There are currently outstanding stock option awards issued from the 2005 Plan covering a total of 22,095 shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $12.83 per share and the weighted average remaining contractual term is 5.30 years.
	The 2006 Plan was adopted by the Board of Directors of Viveve and was terminated in conjunction with the Merger. Outstanding stock option awards have been assumed by the Company and will continue to be administered in accordance with the terms of the 2006 Plan until such awards are exercised, expire, terminate or are forfeited. There are currently outstanding stock option awards issued from the 2006 Plan covering a total of 322,069 shares of the Company’s common stock and no shares available for future awards. The weighted average exercise price of the outstanding stock options is $1.54 per share and the weighted average remaining contractual term is 7.82 years. Additionally, prior to the Merger, the Board of Directors voted to accelerate the vesting of all unvested options that were outstanding as of the date of the Merger such that all options would be immediately vested and exercisable by the holders. Furthermore, at the Merger, outstanding options to purchase shares of Viveve, Inc. common stock issued from the 2006 Plan were converted into options to purchase shares of the Company’s Common Stock (rounded down to the nearest whole share). The number of shares of the Company’s common stock into which the 2006 Plan options were converted was determined by multiplying the number of shares covered by each 2006 Plan option by the exchange ratio of 0.0080497. The exercise price of each 2006 Plan option was determined by dividing the exercise price of each 2006 Plan option immediately prior to the Merger by the exchange ratio of 0.0080497 (rounded up to the nearest cent).
	The 2013 Plan was also adopted by PLC's Board of Directors and approved by its stockholders. The 2013 Plan is administered by the Compensation Committee of the Company’s Board of Directors (the “Administrator”). Under the 2013 Plan, the Company may grant to eligible partcipants equity awards which may take the form of stock options (both incentive stock options and non-qualified stock options), stock appreciation rights, restricted, deferred or unrestricted stock awards, performance based awards or dividend equivalent rights. Awards may be granted to officers, employees, non-employee Directors (as defined in the 2013 Plan) and other key persons (including consultants and prospective employees). The term of any stock option award may not exceed 10 years and may be subject to vesting conditions, as determined by the Administrator. Options granted generally vest over four years. Incentive stock options may be granted only to employees of the Company or any subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Internal Revenue Code. The exercise price of any stock option award cannot be less than the fair market value of the Company’s common stock, provided, however, that an incentive stock option granted to an employee who owns more than 10% of the Company’s outstanding voting power must have an exercise price of no less than 110% of the fair market value of the Company’s common stock and a term that does not exceed five years. There are currently outstanding stock option awards issued from the 2013 Plan covering a total of 1,947,619 shares of the Company’s common stock and there remain reserved for future awards 841,739 shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $0.80 per share, and the remaining contractual term is 9.62 years. Concurrent with the Merger, the stockholders approved an amendment to the 2013 Plan to increase the number of shares reserved under the 2013 Plan from 113,826 to 3,111,587.
	Activity under the 2005 Plan, the 2006 Plan and the 2013 Plan is as follows:
			Year Ended December 31,
			2014														2013
			Number				Weighted Average Exercise Price				Weighted Average Remaining Contractual Term (years)			Aggregate			Number				Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate
			of											Intrinsic			of								Intrinsic
			Shares											Value			Shares								Value
														(in thousands)											(in thousands)
	Options outstanding, beginning of year			363,413			$	1.24				8.8						360,531			$	1.24		9.74
	Options granted			1,901,476			$	0.6										95,581			$	1.24
	Options assumed from PLC			68,238			$	10.24										-			$	-
	Options exercised			(160	)		$	0.12										-			$	-
	Options canceled			(41,184	)		$	1.83										(92,699	)		$	1.24
	Options outstanding, end of year			2,291,783			$	1.02				9.32		$	-			363,413			$	1.24		8.8	$	-
	Vested and exercisable and expected to vest, end of year			2,099,687			$	1.06				9.29		$	-			348,865			$	1.24		8.8	$	-
	Vested and exercisable, end of year			519,901			$	2.45				7.89		$	-			120,955			$	2.48		8.6	$	-
	As of December 31, 2014, the Company had 841,739 shares available for grant.
	The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of December 31, 2014.
	The options outstanding and exercisable as of December 31, 2014 are as follows (in thousands except share and per share data):
						Options Outstanding										Options Exercisable
													Weighted
						Number				Weighted			Average			Number				Weighted
						Outstanding				Average			Remaining			Exercisable				Average
	Range of					as of				Exercise			Contractual			as of				Exercise
	Exercise Prices					31-Dec-14				Price			Term (Years)			31-Dec-14				Price
	$0.60						1,901,476			$	0.6			9.64			129,594			$	0.6
	$1.24						312,373			$	1.24			7.9			312,373			$	1.24
	$7.00	-	$9.00				58,603			$	8.64			7.46			58,603			$	8.64
	$12.00	-	$18.63				19,081			$	15.29			6.54			19,081			$	15.29
	$37.00						250			$	37			3.47			250			$	37
							2,291,783			$	1.02			9.32			519,901			$	2.45
	Stock-Based Compensation
	During the year ended December 31, 2014, the Company granted stock options to employees to purchase 1,901,476 shares of common stock with a weighted-average grant date fair value of $0.32 per share. Stock-based compensation expense recognized during the year ended December 31, 2014 and 2013 was $184,000 and $87,000, respectively. As of December 31, 2014, the total unrecognized compensation cost in connection with unvested stock options was approximately $496,000. These costs are expected to be recognized over a period of approximately 3.73 years. The aggregate intrinsic value of options outstanding as of December 31, 2014 and 2013 was $0. The aggregate intrinsic value of options exercised during the years ended December 31, 2014 and 2013 was $0. The total estimated grant date fair value of options vested during the years ended December 31, 2014 and 2013 was $44,000 and $140,000, respectively.
	The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following assumptions:
			Year Ended
			Decenber 31,
			2014				2013
	Expected term (in years)			5				5
	Average volatility			61	%			68	%
	Risk-free interest rate			1.8	%			0.84	%
	Dividend yield			0	%			0	%
	Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends and does not anticipate issuing any dividends in the future.
	The following table shows stock-based compensation expense included in the consolidated statements of operations for the years ended December 31, 2014 and 2013 (in thousands):
			Year Ended
			Year Ended December 31,
			2014				2013
	Research and development		$	5			$	-
	Selling, general and administrative			179				87
	Total		$	184			$	87
	Prior to the merger, the Company’s Board of Directors approved the acceleration of vesting of all unvested stock options that were outstanding under the 2006 Plan as of the date of the merger. For the year ended December 31, 2014, the Company recorded additional stock-based compensation expense (primarily in selling, general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2014) of approximately $103,000 associated with the acceleration of vesting of approximately 140,000 affected stock options.

Note_12_Income_Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12	Income Taxes
	No provision for income taxes has been recorded due to the net operating losses incurred from inception to date, for which no benefit has been recorded.
	A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows:
			Year Ended
			December 31,
			2014			2013
	Income tax provision (benefit) at statutory rate			(34	)%		(34	)%
	State income taxes, net of federal benefit			(6	)%		(6	)%
	Merger transaction costs			6	%		-
	Change in valuation allowance			37	%		39	%
	Other			(3	)%		1	%
	Effective tax rate			0	%		0	%
	The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands):
			December 31,
			2014			2013
	Deferred tax assets:
	Net operating loss carryforwards		$	5,770		$	4,203
	Capitalized start up costs			7,751			7,156
	Research and development credits			189			162
	Accruals and reserves			169			99
	Total deferred tax assets			13,879			11,620
	Deferred tax liabilities:
	Depreciation and amortization			(13	)		(11	)
	Valuation allowance			(13,866	)		(11,609	)
	Net deferred tax assets		$	-		$	-
	The Company has recorded a full valuation allowance for its deferred tax assets based on it past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance increased by approximately $2,257,000 and $1,642,000 during the years ended December 31, 2014 and 2013, respectively.
	As of December 31, 2014, the Company has net operating loss carryforwards for federal and state income tax purposes of approximately $14,487,000 and $14,475,000 respectively, which expire beginning in the year 2017.
	The Company also has federal and California research and development tax credits of approximately $165,000 and $159,000 respectively. The federal research credits will begin to expire in 2027 and the California research and development credits have no expiration date.
	The above net operating losses and research and development credits are subject to Sections 382 and 383 of the Internal Revenue Code. In the event of a change in ownership as defined by these code sections, the usage of the above mentioned net operating losses and research and development credits may be limited.
	As of December 31, 2014, the Company had not accrued any interest or penalties related to uncertain tax positions.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
			Year Ended
			December 31,
			2014			2013
	Balance as of the beginning of the year		$	83		$	83
	Additions based upon tax positions related to the current year			14			-
	Balance as of the end of the year		$	97		$	83
	If the ending balance of $97,000 of unrecognized tax benefits as of December 31, 2014 were recognized, none of the recognition would affect the income tax rate. The Company does not anticipate any material change in its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business.
	The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examination due to the carryover of unused net operating losses and tax credits.

Note_13_Related_Party_Transact

Note 13 - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	13.      Related Party Transactions
	In June 2006, the Company entered into a Development and Manufacturing Agreement with Stellartech Research Corporation (the “Agreement”). The Agreement was amended on October 4, 2007. Under the Agreement, the Company agreed to purchase 300 generators manufactured by Stellartech. As of December 31, 2014, the Company has purchased 23 units. The price per unit is variable and dependent on the volume and timing of units ordered. In conjunction with the Agreement, Stellartech purchased 300,000 shares of common stock at par value. These shares are subject to a right of repurchase by the Company, which lapse over a four-year period. As of December 31, 2012, none of the shares of common stock were subject to repurchase. Under the Agreement, the Company paid Stellartech $484,000 and $33,000 for goods and services during the years ended December 31, 2014 and 2013, respectively.

Note_14_Segments_and_Geographi

Note 14 - Segments and Geographic Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	14.      Segments and Geographic Information
	Revenue from unaffiliated customers by geographic area were as follows (in thousands):
		Year Ended December 31,
		2014		2013
	Hong Kong	$	43	$	-
	Japan		40		152
	Canada		4		-
	Other		3		-
		$	90	$	152
	The Company’s long-lived assets by geographic area were as follows (in thousands):
		December 31,
		2014		2013
	United States	$	60	$	98
	Canada		21		30
	Europe		106		-
		$	187	$	128
	Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date.

Note_15_Subsequent_Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15.      Subsequent Events
	In January 2015, the Company entered into an amendment to the operating lease agreement for its current office and laboratory facilities which extended the lease term to March 2017. Future minimum payments under the lease, as amended, are as follows:
	Year Ending December 31,
	2015	$	199
	2016		229
	2017		58
	Total minimum lease payments	$	486
	In February 2015, the Company entered into an amendment to the loan and security agreement dated September 30, 2014, whereby $500,000 of the second tranche was provided to us on February 19, 2015 and the remaining $1 million was subject to (i) evidence acceptable to the lender of at least 50% enrollment in the OUS Clinical Trial no later than March 9, 2015 and (ii) documentation or other evidence acceptable to the lender of a prospective equity financing to close by April 15, 2015. On March 16, 2015, we have received an additional $500,000 in connection with a drawdown of funds from the second tranche. Additionally, the amendment modified the third tranche of $1 million to permit the Company to draw down at any time during the period beginning on the date that we have provided evidence acceptable to the lender of positive interim 3-month results from the OUS Clinical Trial until June 30, 2015. The amendment also modifies certain covenants, including, but not limited to, covenants to achieve specified revenue levels, OUS Clinical Trial milestones and capital raising requirements.
	In connection with the loan amendment, the Company also amended the terms of the warrant issued to the lender to provide for an automatic increase of the number of shares the lender may acquire in the event the Company fails to meet certain covenants to achieve certain OUS Clinical Trial milestones or capital raising requirements as set forth in the loan agreement, as amended, by a number equal to the quotient derived by dividing (i) 1% of the principal balance outstanding under the loan agreement by (ii) the exercise price of $0.53 per share.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share
	The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, convertible preferred stock, warrants to purchase convertible preferred stock and common stock, stock options and rights to common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Potential common shares will always be anti-dilutive for periods in which the Company has reported a net loss. Diluted net loss per share is the same as basic net loss per share for the years ended December 31, 2014 and 2013.
	For the years ended December 31, 2014 and 2013, the following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive.
		Year Ended
		December 31,
		2014		2013
	Convertible preferred stock		-		195,062,650
	Warrants to purchase convertible preferred stock		-		16,680,324
	Stock options to purchase common stock		2,291,783		363,413
	Warrants to purchase common stock		1,793,887		-
	Rights to common stock		566,038		-
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity of three months or less, at the time of purchase, to be cash equivalents. The Company’s cash and cash equivalents are deposited in demand accounts primarily at one financial institution. Deposits in this institution may, from time to time, exceed the federally insured amounts.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties
	To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows.
	The Company’s products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse impact on the Company’s financial results, financial position and future cash flows.
	The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products.
	During the year ended December 31, 2014, two customers accounted for 91% of the Company’s revenue. During the year ended December 31, 2013, three customers accounted for 100% of the Company’s revenue.
Inventory, Policy [Policy Text Block]	Inventory
	Inventory is stated at the lower of cost or market. Cost is determined on an actual cost basis on a first-in, first-out method. Lower of cost or market is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory. Excess and obsolete inventory is charged to cost of revenue and a new lower-cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
	As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five years. The amortization of the demos is charged to selling, general and administrative expense and the demos are included in the medical equipment line of the property and equipment balance on the consolidated balance sheet as of December 31, 2014 and 2013.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight line method over their estimated useful lives of three to seven years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful lives or the life of the lease. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	Preferred Stock Warrants
	Freestanding warrants and other similar instruments related to shares that are redeemable are classified as liabilities on the balance sheet. The warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense), net. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the preferred stock warrants.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	The Company recognizes revenue from the sale of its products, the Viveve® System, single-use treatment tips and ancillary consumables. Revenue is recognized upon delivery, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of Viveve’s products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance outside the U.S. and currently sells the Viveve System in Canada, Hong Kong and Japan.
	The Company does not provide its customers with a contractual right of return.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty
	The Company’s products are generally subject to a one year warranty, which provides for the repair, rework or replacement of products (at its option) that fail to perform within stated specification. The Company has assessed the historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual going forward.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs
	The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue.
Advertising Costs, Policy [Policy Text Block]	Advertising Costs
	Advertising costs are charged to general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2014 and 2013.
Research and Development Expense, Policy [Policy Text Block]	Research and Development
	Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.
Income Tax, Policy [Policy Text Block]	Income Taxes
	The Company account for income taxes in accordance with Accounting Standards Codification (“ASC”) 740, Income Taxes (“ASC 740”), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. Under ASC 740, the liability method is used in accounting for income taxes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred tax asset will not be realized. We evaluate annually the realizability of our deferred tax assets by assessing our valuation allowance and by adjusting the amount of such allowance, if necessary. The factors used to assess the likelihood of realization include our forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. As of December 31, 2014 and 2013, the Company has recorded a full valuation allowance for our deferred tax assets based on our historical loss and the uncertainty regarding our ability to project future taxable income. In future periods if we are able to generate income we may reduce or eliminate the valuation allowance.
Income Tax Uncertainties, Policy [Policy Text Block]	Accounting for Uncertainty in Income Taxes
	The Company accounts for uncertain tax positions in accordance with ASC 740.  ASC 740 seeks to reduce the diversity in practice associated with certain aspects of measurement and recognition in accounting for income taxes. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax provision that an entity takes or expects to take in a tax return. Additionally, ASC 740 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Under ASC 740, an entity may only recognize or continue to recognize tax positions that meet a "more likely than not" threshold. In accordance with our accounting policy, we recognize accrued interests and penalties related to unrecognized tax benefits as a component of income tax.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Accounting for Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation (“ASC 718”) which establishes accounting for stock-based awards exchanged for employee services. Accordingly, share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award.
	We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock.
	Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss
	Comprehensive loss represents the changes in equity of an enterprise, except those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2014 and 2013, the Company’s comprehensive loss is the same as its net loss.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards
	In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual and interim periods beginning after December 15, 2016. We are currently evaluating the impact that this standard will have on our consolidated financial statements.
	In June 2014, the FASB issued ASU No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved After a Requisite Service Period” (“ASU 2014-12”). Companies commonly issue share-based payment awards that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. The performance target should not be reflected in estimating the grant date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. ASU 2014-12 will be effective for the Company’s fiscal years beginning fiscal 2016 and interim reporting periods within that year, using either the retrospective or prospective transition method. Early adoption is permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements.
	In June 2014, the FASB issued ASU 2014-10, “Development Stage Entities (Topic 915):  Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in topic 810, Consolidation” (“ASU 2014-10”). ASU 2014-10 removes the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. ASU 2014-10 also eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. The amendments in ASU 2014-10 will be effective retrospectively except for the clarification to Topic 275, which shall be applied prospectively for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. We elected to early adopt the provisions of ASU 2014-10 in the second quarter of 2014.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements and disclosures.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		Year Ended
		December 31,
		2014		2013
	Convertible preferred stock		-		195,062,650
	Warrants to purchase convertible preferred stock		-		16,680,324
	Stock options to purchase common stock		2,291,783		363,413
	Warrants to purchase common stock		1,793,887		-
	Rights to common stock		566,038		-

Note_3_Fair_Value_Measurements1

Note 3 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]			Assets and Liabilities at Fair Value as of December 31, 2013
			Quoted prices in active markets for identical assets			Significant				Significant unobservable
						other observable inputs				inputs
			Level 1			Level 2				Level 3		Total
	Assets
			$	-		$	-			$	-	$	-
	Total assets		$	-		$	-			$	-	$	-
	Liabilities
	Preferred stock warrant liabilities		$	-		$	-			$	624	$	624
	Total liabilities		$	-		$	-			$	624	$	624
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair value as of December 31, 2012		$	686
	Change in fair value recorded in other income (expense), net			(62	)
	Fair value as of December 31, 2013			624
	Change in fair value recorded in other income (expense), net			(52	)
	Extinguishment of warrant liabilities pursuant to the Merger Agreement			(572	)
	Fair value as of December 31, 2014		$	-
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]		Fair Value as of
		31-Dec-13			Valuation	Unobservable	Range
		(in thousands)			Techniques	Input	(Weighted-Average)
	Preferred stock warrant liabilities	$	624		Black-Scholes	Preferred series
					option pricing	prices		$0.04	-	$0.44	($0.06)
					model
						Volatility		70.60%	-	84.20%	-76%

Note_4_Property_and_Equipment_1

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]		Life		December 31,
		(in years)		2014			2013
	Medical equipment		5	$	367		$	277
	Computer equipment		3		39			32
	Furniture and fixtures		7		13			13
					419			322
	Less: Accumulated depreciation and amortization				(232	)		(194	)
	Property and equipment, net			$	187		$	128

Note_5_Accrued_Liabilities_Tab

Note 5 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]		December 31,
		2014		2013
	Accrued professional fees	$	117	$	15
	Accrued vacation		86		81
	Accrued interest		-		237
	Accrued loan balloon payment		-		76
	Accrued loan restructuring fees		-		27
	Accrued severence pay		-		59
	Other accruals		20		21
	Total accrued liabilities	$	223	$	516

Note_6_Note_Payable_Tables

Note 6 - Note Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Year Ending December 31,
	2015	$	293
	2016		1,095
	2017		1,045
	2018		337
	Total Payments		2,770
	Less: Amount representing interest		(270	)
	Present value of obligations		2,500
	Less: Notes payable, current portion		2,500
	Note payable, noncurrent portion	$	-

Note_8_Commitments_and_Conting1

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31,
	2015	$	31
	Total minimum lease payments	$	31

Note_10_Convertible_Preferred_1

Note 10 - Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]						Number of
						Shares
		Series				Outstanding		Fair Value
		Exercisable	Expiration	Exercise		Under		December 31,
	Issuance Date	for	Date	Price		Warrants		2013
	Dec-08	Series A	2-Dec-18	$	0.61		196,721	$	44,000
	Apr-09	Series A	2-Apr-19		0.61		245,900		58,000
	Nov-10	Series A	19-Nov-20		0.61		163,934		47,000
	May-11	Series B	6-May-21		0.05		2,000,000		54,000
	Jun-11	Series B	30-Jun-21		0.05		4,000,000		108,000
	Sep-11	Series B	9-Sep-21		0.05		4,000,000		108,000
	Nov-11	Series B	30-Nov-21		0.05		1,000,000		28,000
	Dec-11	Series B	19-Dec-21		0.05		1,000,000		28,000
	Jan-12	Series B	31-Jan-22		0.05		910,445		28,000
	Feb-12	Series B	28-Feb-22		0.05		738,535		23,000
	Apr-12	Series B	16-Apr-22		0.05		2,351,019		73,000
	Apr-12	Series A	19-Apr-22		0.61		73,770		25,000
							16,680,324	$	624,000

Note_11_Summary_of_Stock_Optio1

Note 11 - Summary of Stock Options (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]			Year Ended December 31,
			2014														2013
			Number				Weighted Average Exercise Price				Weighted Average Remaining Contractual Term (years)			Aggregate			Number				Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate
			of											Intrinsic			of								Intrinsic
			Shares											Value			Shares								Value
														(in thousands)											(in thousands)
	Options outstanding, beginning of year			363,413			$	1.24				8.8						360,531			$	1.24		9.74
	Options granted			1,901,476			$	0.6										95,581			$	1.24
	Options assumed from PLC			68,238			$	10.24										-			$	-
	Options exercised			(160	)		$	0.12										-			$	-
	Options canceled			(41,184	)		$	1.83										(92,699	)		$	1.24
	Options outstanding, end of year			2,291,783			$	1.02				9.32		$	-			363,413			$	1.24		8.8	$	-
	Vested and exercisable and expected to vest, end of year			2,099,687			$	1.06				9.29		$	-			348,865			$	1.24		8.8	$	-
	Vested and exercisable, end of year			519,901			$	2.45				7.89		$	-			120,955			$	2.48		8.6	$	-
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]						Options Outstanding										Options Exercisable
													Weighted
						Number				Weighted			Average			Number				Weighted
						Outstanding				Average			Remaining			Exercisable				Average
	Range of					as of				Exercise			Contractual			as of				Exercise
	Exercise Prices					31-Dec-14				Price			Term (Years)			31-Dec-14				Price
	$0.60						1,901,476			$	0.6			9.64			129,594			$	0.6
	$1.24						312,373			$	1.24			7.9			312,373			$	1.24
	$7.00	-	$9.00				58,603			$	8.64			7.46			58,603			$	8.64
	$12.00	-	$18.63				19,081			$	15.29			6.54			19,081			$	15.29
	$37.00						250			$	37			3.47			250			$	37
							2,291,783			$	1.02			9.32			519,901			$	2.45
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]			Year Ended
			Decenber 31,
			2014				2013
	Expected term (in years)			5				5
	Average volatility			61	%			68	%
	Risk-free interest rate			1.8	%			0.84	%
	Dividend yield			0	%			0	%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]			Year Ended
			Year Ended December 31,
			2014				2013
	Research and development		$	5			$	-
	Selling, general and administrative			179				87
	Total		$	184			$	87

Note_12_Income_Taxes_Tables

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		Year Ended
		December 31,
		2014			2013
	Income tax provision (benefit) at statutory rate		(34	)%		(34	)%
	State income taxes, net of federal benefit		(6	)%		(6	)%
	Merger transaction costs		6	%		-
	Change in valuation allowance		37	%		39	%
	Other		(3	)%		1	%
	Effective tax rate		0	%		0	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	5,770		$	4,203
	Capitalized start up costs		7,751			7,156
	Research and development credits		189			162
	Accruals and reserves		169			99
	Total deferred tax assets		13,879			11,620
	Deferred tax liabilities:
	Depreciation and amortization		(13	)		(11	)
	Valuation allowance		(13,866	)		(11,609	)
	Net deferred tax assets	$	-		$	-
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]		Year Ended
		December 31,
		2014			2013
	Balance as of the beginning of the year	$	83		$	83
	Additions based upon tax positions related to the current year		14			-
	Balance as of the end of the year	$	97		$	83

Note_14_Segments_and_Geographi1

Note 14 - Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Areas [Table Text Block]		Year Ended December 31,
		2014		2013
	Hong Kong	$	43	$	-
	Japan		40		152
	Canada		4		-
	Other		3		-
		$	90	$	152
Long-lived Assets by Geographic Areas [Table Text Block]		December 31,
		2014		2013
	United States	$	60	$	98
	Canada		21		30
	Europe		106		-
		$	187	$	128

Note_15_Subsequent_Events_Tabl

Note 15 - Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2014
Note 15 - Subsequent Events (Tables) [Line Items]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31,
	2015	$	31
	Total minimum lease payments	$	31
Subsequent Event [Member]
Note 15 - Subsequent Events (Tables) [Line Items]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31,
	2015	$	199
	2016		229
	2017		58
	Total minimum lease payments	$	486

Note_1_The_Company_and_Basis_o1

Note 1 - The Company and Basis of Presentation (Details) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended	0 Months Ended
	Sep. 23, 2014	Dec. 31, 2014	Dec. 31, 2014	9-May-14	Dec. 31, 2013
Note 1 - The Company and Basis of Presentation (Details) [Line Items]
Extinguishment of Debt, Amount			$5,397,000
Extinguishment of Warrant Liabilities	572,000		572,000
Conversion of Stock, Shares Issued (in Shares)	3,743,282
Proceeds from Issuance of Private Placement	6,000,000		4,204,000
Debt Conversion, Original Debt, Amount	1,546,000		1,546,000
Stock Issued During Period, Shares, New Issues (in Shares)	11,305,567
Warrant Term	5 years	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	940,189	382,000	382,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$0.53	$0.53	$0.53
Retained Earnings (Accumulated Deficit)		-36,085,000	-36,085,000		-29,905,000
Accrued Interest [Member] | Convertible Debt [Member]
Note 1 - The Company and Basis of Presentation (Details) [Line Items]
Extinguishment of Debt, Amount	522,000
Accrued Interest [Member] | GBS [Member]
Note 1 - The Company and Basis of Presentation (Details) [Line Items]
Debt Conversion, Original Debt, Amount				211,000
Convertible Debt [Member]
Note 1 - The Company and Basis of Presentation (Details) [Line Items]
Extinguishment of Debt, Amount	4,875,000
Viveve [Member]
Note 1 - The Company and Basis of Presentation (Details) [Line Items]
Conversion of Stock, Shares Issued (in Shares)	3,743,282
Percentage of Total Common Stock Attributable to Viveve Capital Stock Converted	62.00%
Payment to Each Non-Accredited Investors For Converted Shares Upon Merger	16,000
GBS [Member]
Note 1 - The Company and Basis of Presentation (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)	943,596			943,596
Debt Conversion, Original Debt, Amount				$1,750,000

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 30, 2013	Dec. 31, 2013
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Number of Financial Institutions	1
Warranty Period	1 year
Medical Equipment, Sales Demos [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5 years
Two Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Number of Customers	2
Concentration Risk, Percentage	91.00%
Three Customers [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Number of Customers			3
Concentration Risk, Percentage		100.00%
Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		three
Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		seven

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Antidilutive Securities	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Convertible Securities, Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		195,062,650
Preferred Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		16,680,324
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,291,783	363,413
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,793,887
Rights to Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	566,038

Note_3_Fair_Value_Measurements2

Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items]
Preferred stock warrant liabilities	$624
Total liabilities	624
Fair Value, Inputs, Level 3 [Member]
Note 3 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value [Line Items]
Preferred stock warrant liabilities	624
Total liabilities	$624

Note_3_Fair_Value_Measurements3

Note 3 - Fair Value Measurements (Details) - Summary of Changes in Fair Value of Preferred Stock Warrant Liabilities (USD $)	1 Months Ended	12 Months Ended
	Sep. 23, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of Changes in Fair Value of Preferred Stock Warrant Liabilities [Abstract]
Fair value			$624,000	$686,000
Change in fair value recorded in other income (expense), net		-52,000	-62,000
Extinguishment of warrant liabilities pursuant to the Merger Agreement	($572,000)	($572,000)

Note_3_Fair_Value_Measurements4

Note 3 - Fair Value Measurements (Details) - Summary of the Valuation Techniques for Fair Value of Preferred Stock Warrant Liabilities (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Preferred stock warrant liabilities	624,000	$686,000
Warrant [Member] | Preferred Stock Warrant Liabilities [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Preferred stock warrant liabilities	Black-Scholes
	Black-Scholes
Warrant [Member] | Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
	0.04
	-0.04
	70.60%
	-70.60%
Warrant [Member] | Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
	0.44
	-0.44
	84.20%
	-84.20%
Warrant [Member] | Weighted Average [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
	0.06
	-0.06
	76.00%
	-76.00%
Warrant [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Preferred stock warrant liabilities	option pricing
	option pricing
Preferred Stock Warrant Liabilities [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Preferred stock warrant liabilities	624,000

Note_4_Property_and_Equipment_2

Note 4 - Property and Equipment, Net (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation	$56,000	$66,000

Note_4_Property_and_Equipment_3

Note 4 - Property and Equipment, Net (Details) - Equipment, Furniture and Leasehold Improvements (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$419	$322
Less: Accumulated depreciation and amortization	-232	-194
Property and equipment, net	187	128
Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Property and equipment, gross	367	277
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Property and equipment, gross	39	32
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Property and equipment, gross	$13	$13

Note_5_Accrued_Liabilities_Det

Note 5 - Accrued Liabilities (Details) - Accrued Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]
Accrued professional fees	$117	$15
Accrued vacation	86	81
Accrued interest		237
Accrued loan balloon payment		76
Accrued loan restructuring fees		27
Accrued severence pay		59
Other accruals	20	21
Total accrued liabilities	$223	$516

Note_6_Note_Payable_Details

Note 6 - Note Payable (Details) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Sep. 23, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Feb. 28, 2013

31-May-13

Sep. 30, 2013

Jul. 31, 2013

Nov. 30, 2013

Jan. 31, 2014

Feb. 28, 2014

Oct. 01, 2014

Jun. 30, 2014

Apr. 30, 2012

Sep. 30, 2014

Sep. 30, 2014

Note 6 - Note Payable (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

940,189

382,000

382,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$0.53

$0.53

$0.53

Accrued Loan Balloon Payment

$76,000

Notes Payable, Current

2,500,000

2,500,000

1,463,000

Accrued Debt Restructuring Costs

27,000

Warrant Term

5 years

5 years

Long-term Debt

2,770,000

2,770,000

April 2012 Warrants [Member]

Note 6 - Note Payable (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

73,770

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$0.61

Related to Final Payment [Member] | April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Interest Expense, Debt

9,000

35,000

Related to the Restructuring Payment [Member] | April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Interest Expense, Debt

20,000

Debt Instrument, Restructuring Fee

27,000

Bridge Loans on or before April 30, 2013 [Member] | April 2012 Term Loan [Member] | Minimum [Member]

Note 6 - Note Payable (Details) [Line Items]

Contingent Bridge Loan Proceeds

500,000

Bridge Loans on or before April 30, 2013 [Member] | April 2012 Term Loan [Member] | Maximum [Member]

Note 6 - Note Payable (Details) [Line Items]

Contingent Bridge Loan Proceeds

1,500,000

Bridge Loans on or before September, 2013 [Member] | April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Contingent Bridge Loan Proceeds

500,000

Bridge Loans on or before August 28, 2103 [Member] | April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Contingent Bridge Loan Proceeds

500,000

500,000

Bridge Loans on or before October 28, 2013 [Member] | April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Contingent Bridge Loan Proceeds

500,000

Bridge Loan on or before December 27, 2013 [Member] | April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Contingent Bridge Loan Proceeds

500,000

Bridge Loans on or before February 25, 2014 [Member] | April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Contingent Bridge Loan Proceeds

500,000

Bridge Loans on or before April 25, 2014 [Member] | April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Contingent Bridge Loan Proceeds

500,000

Amendment to the January 2014 Amendment [Member] | April 2012 Term Loan [Member] | Maximum [Member]

Note 6 - Note Payable (Details) [Line Items]

Debt Instrument, Restructuring Fee

5,000

First Tranche [Member] | September 2014 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Proceeds from Issuance of Debt

2,500,000

Repayments of Debt

1,631,000

April 2012 Term Loan [Member] | Minimum [Member]

Note 6 - Note Payable (Details) [Line Items]

Debt Instrument, Restructuring Fee

5,000

5,000

5,000

April 2012 Term Loan [Member] | Maximum [Member]

Note 6 - Note Payable (Details) [Line Items]

Debt Instrument, Restructuring Fee

15,000

20,000

15,000

April 2012 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Debt Instrument, Face Amount

2,135,159

Debt Instrument, Repayment of Principal and Interest, Number of Installments

30

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Additional Percentage of Principal Owed Upon Final Payment

4.00%

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

85,000

Accrued Loan Balloon Payment

0

0

76,000

Notes Payable, Current

0

0

1,463,000

Debt Instrument, Restructuring Fee

15,000

10,000

10,000

10,000

10,000

47,500

Contingent Equity Event Proceeds

10,000,000

7,000,000

Accrued Debt Restructuring Costs

0

0

27,000

September 2014 Term Loan [Member]

Note 6 - Note Payable (Details) [Line Items]

Debt Instrument, Face Amount

5,000,000

5,000,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

471,698

471,698

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$0.53

$0.53

Debt Instrument, Interest Rate, Stated Percentage

5.25%

5.25%

Warrant Term

10 years

Long-term Debt

$2,500,000

$2,500,000

Note_6_Note_Payable_Details_Su

Note 6 - Note Payable (Details) - Summary of Note Payable (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of Note Payable [Abstract]
2015	$293
2016	1,095
2017	1,045
2018	337
Total Payments	2,770
Less: Amount representing interest	-270
Present value of obligations	2,500
Less: Notes payable, current portion	2,500	1,463
Note payable, noncurrent portion	$0

Note_7_Related_Party_Convertib1

Note 7 - Related Party Convertible Bridge Notes (Details) (USD $)

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Nov. 30, 2012

Feb. 13, 2014

Feb. 13, 2013

Jun. 30, 2013

Apr. 30, 2013

Sep. 27, 2013

Nov. 12, 2013

Dec. 27, 2013

Mar. 05, 2014

31-May-14

Aug. 31, 2013

Dec. 31, 2013

Dec. 31, 2014

Aug. 07, 2013

Jul. 07, 2014

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Interest Payable, Current

$237,000

Related Party Convertible Bridge Notes [Member] | November 2012 Convertible Promissory Note [Member]

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Debt Instrument, Face Amount

1,000,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Minimum Gross Proceeds from Issuance of Common or Preferred Stock

5,000,000

Convertible Debt

1,000,000

0

Interest Payable, Current

89,000

Related Party Convertible Bridge Notes [Member] | 2013 Note Purchase Agreement [Member]

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Minimum Gross Proceeds from Issuance of Common or Preferred Stock

5,000,000

Convertible Debt

2,500,000

0

Interest Payable, Current

130,000

Maximum Authorized Convertible Promissory Notes Issuable

1,500,000

2,500,000

Proceeds from Convertible Debt

1,000,000

500,000

500,000

Debt Instrument, Convertible, Conversion Price as a Percentage of Purchase Price

80.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$0.05

Debt Instrument, Redemption Price, Percentage of Principal Amount and Accrued and Unpaid Interest Redeemed

300.00%

Related Party Convertible Bridge Notes [Member] | September 2013 Note Purchase Agreement [Member]

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Minimum Gross Proceeds from Issuance of Common or Preferred Stock

5,000,000

Convertible Debt

500,000

0

Interest Payable, Current

10,000

Maximum Authorized Convertible Promissory Notes Issuable

500,000

Debt Instrument, Convertible, Conversion Price as a Percentage of Purchase Price

70.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$0.05

Related Party Convertible Bridge Notes [Member] | November 2013 Note Purchase Agreement [Member]

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Minimum Gross Proceeds from Issuance of Common or Preferred Stock

5,000,000

Convertible Debt

500,000

0

Interest Payable, Current

5,000

Maximum Authorized Convertible Promissory Notes Issuable

500,000

Debt Instrument, Convertible, Conversion Price as a Percentage of Purchase Price

70.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$0.05

Related Party Convertible Bridge Notes [Member] | December 2013 Note Purchase Agreement [Member]

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.00%

Minimum Gross Proceeds from Issuance of Common or Preferred Stock

5,000,000

Convertible Debt

375,000

0

Interest Payable, Current

1,000

Maximum Authorized Convertible Promissory Notes Issuable

375,000

Debt Instrument, Convertible, Conversion Price as a Percentage of Purchase Price

70.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$0.05

Related Party Convertible Bridge Notes [Member] | March 2014 Note Purchase Agreement [Member]

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.00%

Maximum Authorized Convertible Promissory Notes Issuable

1,250,000

Proceeds from Convertible Debt

200,000

1,050,000

Related Party Convertible Bridge Notes [Member] | July 2013 Note Purchase Agreement [Member]

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

9.00%

Maximum Authorized Convertible Promissory Notes Issuable

250,000

Related Party Convertible Bridge Notes [Member] | 2013 Note Purchase Agreement [Member]

Note 7 - Related Party Convertible Bridge Notes (Details) [Line Items]

Maximum Authorized Convertible Promissory Notes Issuable

2,000,000

Proceeds from Convertible Debt

$500,000

Note_8_Commitments_and_Conting2

Note 8 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, Rent Expense	$171,000	$171,000

Note_8_Commitments_and_Conting3

Note 8 - Commitments and Contingencies (Details) - Future Minimum Lease Payments (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Future Minimum Lease Payments [Abstract]
2015	$31
Total minimum lease payments	$31

Note_9_Common_Stock_Details

Note 9 - Common Stock (Details) (USD $)	0 Months Ended	1 Months Ended		3 Months Ended	12 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended
	Dec. 29, 2014	Sep. 23, 2014	31-May-14	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	9-May-14	Sep. 30, 2014
Note 9 - Common Stock (Details) [Line Items]
Conversion of Stock, Shares Issued		3,743,282
Conversion of Stock, Exchange Ratio		0.0080497
Debt Conversion, Original Debt, Amount (in Dollars)		$1,546,000			$1,546,000
Stock Issued During Period, Shares, New Issues		11,305,567
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		940,189		382,000	382,000		382,000
Proceeds from Issuance of Private Placement (in Dollars)		6,000,000			4,204,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$0.53		$0.53	$0.53		0.53
Right to Shares Agreement, Right to Receive Shares, Granted to Investor			432,479
Right to Shares Agreement, Exercise of Right to Receive Shares, Common Stock Issued, Shares	432,479
Right to Shares Agreement, Additional Consideration Paid Upon the Exercise of Right (in Dollars)					0
Right to Shares Agreement, Additional Shares Issuable				0	0		0
Warrant Term		5 years		5 years
Amortization of Debt Discount (Premium) (in Dollars)					48,000
Unamortized Debt Issuance Expense (in Dollars)				574,000	574,000		574,000
Allocated Share-based Compensation Expense (in Dollars)					184,000	87,000
Private Placement [Member]
Note 9 - Common Stock (Details) [Line Items]
Right to Shares Agreement, Common Shares Cancelled					854,989
Right to Shares Agreement, Obligated to Issue, Shares				956,354	956,354		956,354
Right to Shares Agreement, Not Issued Due to Beneficial Ownership Limitations, Shares					101,365
Right to Shares Agreement, Delivery of Shares, Days Obligated					3 days
Right to Shares Agreement, Common Stock, Shares Issued							390,316
Right to Shares Agreement, Shares Reserved But Not Issued				566,038	566,038		566,038
Right to Shares Agreement, Exercise of Right to Receive Shares, Common Stock Issued, Shares	356,666
Right to Shares Agreement, Additional Shares Issuable	0
Warrant [Member] | Minimum [Member]
Note 9 - Common Stock (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate				1.55%
Warrant [Member] | Maximum [Member]
Note 9 - Common Stock (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate				1.65%
Warrant [Member]
Note 9 - Common Stock (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				61.30%
Fair Value Assumptions, Expected Term				5 years
Allocated Share-based Compensation Expense (in Dollars)				137,000
Accrued Interest [Member] | GBS [Member]
Note 9 - Common Stock (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)								211,000
September 2014 Term Loan [Member]
Note 9 - Common Stock (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									471,698
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)									$0.53
Warrant Term									10 years
Warrants and Rights Outstanding (in Dollars)									622,000
Fair Value Assumptions, Expected Dividend Rate									0.00%
Fair Value Assumptions, Expected Volatility Rate									77.00%
Fair Value Assumptions, Risk Free Interest Rate									2.50%
GBS [Member]
Note 9 - Common Stock (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants as Percentage of Outstanding Shares of Common Stock								5.00%
Debt Conversion, Original Debt, Amount (in Dollars)								$1,750,000
Stock Issued During Period, Shares, Other		943,596						943,596

Note_10_Convertible_Preferred_2

Note 10 - Convertible Preferred Stock (Details) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Sep. 23, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 30, 2013

Dec. 31, 2008

Apr. 30, 2009

Nov. 30, 2010

Apr. 30, 2012

Sep. 30, 2014

31-May-11

Jun. 30, 2011

Sep. 30, 2011

Nov. 30, 2011

Dec. 31, 2011

Jan. 31, 2012

Feb. 28, 2012

Dec. 31, 2012

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

940,189

382,000

382,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.53

$0.53

$0.53

Warrant Term

5 years

5 years

Warrant Liabilities Noncurrent

$624,000

$686,000

Fair Value Adjustment of Warrants

-52,000

-62,000

Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | December 2008 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

10,000

7,000

Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | April 2009 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

12,000

9,000

Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | November 2010 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

2,000

2,000

Other Nonoperating Income (Expense) [Member] | Series A Preferred Stock [Member] | April 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

3,000

2,000

Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | April 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

9,000

5,000

Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | May 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

2,000

6,000

Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | June 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

4,000

12,000

Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | September 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

0

12,000

Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | November 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

1,000

2,000

Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | January 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

4,000

2,000

Other Nonoperating Income (Expense) [Member] | Series B Preferred Stock [Member] | February 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Fair Value Adjustment of Warrants

3,000

1,000

Series A Preferred Stock [Member] | December 2008 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

196,721

196,721

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.61

$0.61

Warrant Term

10 years

Warrant Liabilities Noncurrent

44,000

54,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

79.00%

Fair Value Assumptions, Risk Free Interest Rate

2.70%

Fair Value Assumptions, Expected Term

10 years

Series A Preferred Stock [Member] | April 2009 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

245,900

245,900

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.61

$0.61

Warrant Term

10 years

Warrant Liabilities Noncurrent

58,000

70,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

79.00%

Fair Value Assumptions, Risk Free Interest Rate

2.80%

Fair Value Assumptions, Expected Term

10 years

Series A Preferred Stock [Member] | November 2010 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

163,934

163,934

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.61

$0.61

Warrant Term

10 years

Warrant Liabilities Noncurrent

47,000

47,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

79.00%

Fair Value Assumptions, Risk Free Interest Rate

2.90%

Fair Value Assumptions, Expected Term

10 years

Series A Preferred Stock [Member] | April 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

73,770

73,770

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.61

$0.61

Warrant Term

10 years

Warrant Liabilities Noncurrent

25,000

27,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

92.00%

Fair Value Assumptions, Risk Free Interest Rate

1.98%

Fair Value Assumptions, Expected Term

10 years

Series A Preferred Stock [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Preferred Stock, Dividend Rate, Per-Dollar-Amount

$0.05

Preferred Stock, Dividends Per Share, Declared

$0

Preferred Stock, Conversion Price

$0.05

Convertible Preferred Stock, Terms of Conversion, Minimum Aggregate Gross Proceeds Required for Automatic Conversion

30,000,000

Series B Preferred Stock [Member] | April 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

2,351,019

2,351,019

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.05

$0.05

Warrant Term

10 years

Warrant Liabilities Noncurrent

73,000

99,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

84.00%

Fair Value Assumptions, Risk Free Interest Rate

2.00%

Fair Value Assumptions, Expected Term

10 years

Series B Preferred Stock [Member] | May 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

2,000,000

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.05

$0.05

Warrant Term

10 years

Warrant Liabilities Noncurrent

54,000

84,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

84.00%

Fair Value Assumptions, Risk Free Interest Rate

3.20%

Fair Value Assumptions, Expected Term

10 years

Series B Preferred Stock [Member] | June 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

4,000,000

4,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.05

$0.05

Warrant Term

10 years

Warrant Liabilities Noncurrent

108,000

168,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

84.00%

Fair Value Assumptions, Risk Free Interest Rate

3.20%

Fair Value Assumptions, Expected Term

10 years

Series B Preferred Stock [Member] | September 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

4,000,000

4,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.05

$0.05

Warrant Term

10 years

Warrant Liabilities Noncurrent

108,000

168,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

84.00%

Fair Value Assumptions, Risk Free Interest Rate

2.00%

Fair Value Assumptions, Expected Term

10 years

Series B Preferred Stock [Member] | November 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,000,000

1,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.05

$0.05

Warrant Term

10 years

Warrant Liabilities Noncurrent

28,000

42,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

84.00%

Fair Value Assumptions, Risk Free Interest Rate

2.10%

Fair Value Assumptions, Expected Term

10 years

Series B Preferred Stock [Member] | December 2011 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,000,000

1,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.05

$0.05

Warrant Term

10 years

Warrant Liabilities Noncurrent

28,000

41,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

84.00%

Fair Value Assumptions, Risk Free Interest Rate

1.80%

Fair Value Assumptions, Expected Term

10 years

Series B Preferred Stock [Member] | January 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

910,445

910,445

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.05

$0.05

Warrant Term

10 years

Warrant Liabilities Noncurrent

28,000

37,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

84.00%

Fair Value Assumptions, Risk Free Interest Rate

1.80%

Fair Value Assumptions, Expected Term

10 years

Series B Preferred Stock [Member] | February 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

738,535

738,535

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.05

$0.05

Warrant Term

10 years

Warrant Liabilities Noncurrent

23,000

31,000

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Volatility Rate

84.00%

Fair Value Assumptions, Risk Free Interest Rate

1.98%

Fair Value Assumptions, Expected Term

10 years

Series B Preferred Stock [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Preferred Stock, Dividend Rate, Per-Dollar-Amount

$0.00

Preferred Stock, Dividends Per Share, Declared

$0

Preferred Stock, Conversion Price

$0.05

Convertible Preferred Stock, Terms of Conversion, Minimum Aggregate Gross Proceeds Required for Automatic Conversion

$30,000,000

April 2012 Warrants [Member]

Note 10 - Convertible Preferred Stock (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

73,770

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.61

Note_10_Convertible_Preferred_3

Note 10 - Convertible Preferred Stock (Details) - Convertible Preferred Stock Warrants Outstanding (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Sep. 23, 2014	Dec. 31, 2012	Dec. 31, 2008	Apr. 30, 2009	Nov. 30, 2010	Apr. 30, 2012	31-May-11	Jun. 30, 2011	Sep. 30, 2011	Nov. 30, 2011	Dec. 31, 2011	Jan. 31, 2012	Feb. 28, 2012
Class of Warrant or Right [Line Items]
Exercise Price		$0.53	$0.53
Number of Shares Outstanding under Warrants		382,000	940,189
Fair Value	$624,000			$686,000
Series A Preferred Stock [Member] | December 2008 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	2-Dec-18
Exercise Price	$0.61				$0.61
Number of Shares Outstanding under Warrants	196,721				196,721
Fair Value	44,000				54,000
Series A Preferred Stock [Member] | April 2009 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	2-Apr-19
Exercise Price	$0.61					$0.61
Number of Shares Outstanding under Warrants	245,900					245,900
Fair Value	58,000					70,000
Series A Preferred Stock [Member] | November 2010 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	19-Nov-20
Exercise Price	$0.61						$0.61
Number of Shares Outstanding under Warrants	163,934						163,934
Fair Value	47,000						47,000
Series A Preferred Stock [Member] | April 2012 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	19-Apr-22
Exercise Price	$0.61							$0.61
Number of Shares Outstanding under Warrants	73,770							73,770
Fair Value	25,000							27,000
Series B Preferred Stock [Member] | May 2011 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	6-May-21
Exercise Price	$0.05								$0.05
Number of Shares Outstanding under Warrants	2,000,000								2,000,000
Fair Value	54,000								84,000
Series B Preferred Stock [Member] | June 2011 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	30-Jun-21
Exercise Price	$0.05									$0.05
Number of Shares Outstanding under Warrants	4,000,000									4,000,000
Fair Value	108,000									168,000
Series B Preferred Stock [Member] | September 2011 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	9-Sep-21
Exercise Price	$0.05										$0.05
Number of Shares Outstanding under Warrants	4,000,000										4,000,000
Fair Value	108,000										168,000
Series B Preferred Stock [Member] | November 2011 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	30-Nov-21
Exercise Price	$0.05											$0.05
Number of Shares Outstanding under Warrants	1,000,000											1,000,000
Fair Value	28,000											42,000
Series B Preferred Stock [Member] | December 2011 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	19-Dec-21
Exercise Price	$0.05												$0.05
Number of Shares Outstanding under Warrants	1,000,000												1,000,000
Fair Value	28,000												41,000
Series B Preferred Stock [Member] | January 2012 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	31-Jan-22
Exercise Price	$0.05													$0.05
Number of Shares Outstanding under Warrants	910,445													910,445
Fair Value	28,000													37,000
Series B Preferred Stock [Member] | February 2012 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	28-Feb-22
Exercise Price	$0.05														$0.05
Number of Shares Outstanding under Warrants	738,535														738,535
Fair Value	23,000														31,000
Series B Preferred Stock [Member] | April 2012 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Date	16-Apr-22
Exercise Price	$0.05							$0.05
Number of Shares Outstanding under Warrants	2,351,019							2,351,019
Fair Value	73,000							99,000
Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Number of Shares Outstanding under Warrants	16,680,324
Fair Value	$624,000
April 2012 Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price								$0.61
Number of Shares Outstanding under Warrants								73,770

Note_11_Summary_of_Stock_Optio2

Note 11 - Summary of Stock Options (Details) (USD $)	1 Months Ended	12 Months Ended
	Sep. 23, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 22, 2014
Note 11 - Summary of Stock Options (Details) [Line Items]
Conversion of Stock, Exchange Ratio	0.0080497
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		841,739
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,901,476	95,581
Allocated Share-based Compensation Expense		$184,000	$87,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		496,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		44,000	140,000
Stock Options, Acceleration of Vesting, Number		140,000
Selling, General and Administrative Expenses [Member] | Acceleration of Vesting of Approximately 140,000 Affected Stock Options [Member]
Note 11 - Summary of Stock Options (Details) [Line Items]
Allocated Share-based Compensation Expense		103,000
Employee Stock Option [Member]
Note 11 - Summary of Stock Options (Details) [Line Items]
Allocated Share-based Compensation Expense		$184,000	$87,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		3 years 266 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%	0.00%
Holdings Greater than 10% of Shares Outstanding [Member] | The 2013 Plan [Member]
Note 11 - Summary of Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		5 years
Employees [Member]
Note 11 - Summary of Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,901,476
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$0.32
2005 Plan [Member]
Note 11 - Summary of Stock Options (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance		22,095
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		22,095
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$12.83
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		5 years 109 days
The 2006 Stock Option Plan [Member]
Note 11 - Summary of Stock Options (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		322,069
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$1.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		7 years 299 days
Conversion of Stock, Exchange Ratio		0.0080497
The 2013 Plan [Member]
Note 11 - Summary of Stock Options (Details) [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance		841,739
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		1,947,619
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$0.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		9 years 226 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum		10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,111,587			113,826

Note_11_Summary_of_Stock_Optio3

Note 11 - Summary of Stock Options (Details) - Summary of Option Activity Under All Plans (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 11 - Summary of Stock Options (Details) - Summary of Option Activity Under All Plans [Line Items]
Vested and exercisable and expected to vest, end of year	2,099,687	348,865
Vested and exercisable and expected to vest, end of year	$1.06	$1.24
Vested and exercisable and expected to vest, end of year	9 years 105 days	8 years 292 days
Vested and exercisable, end of year	519,901	120,955
Vested and exercisable, end of year	$2.45	$2.48
Vested and exercisable, end of year	7 years 324 days	8 years 219 days
Options granted	1,901,476	95,581
Options granted	$0.60	$1.24
Options assumed from PLC	68,238
Options assumed from PLC	$10.24
Options exercised	-160
Options exercised	$0.12
Options canceled	-41,184	-92,699
Options canceled	$1.83	$1.24
Beginning of Period [Member]
Note 11 - Summary of Stock Options (Details) - Summary of Option Activity Under All Plans [Line Items]
Options outstanding	363,413	360,531
Weighted average exercise price	$1.24	$1.24
Weighted average remaining contractual term	8 years 292 days	9 years 270 days
Options outstanding		363,413
Weighted average exercise price		$1.24
Weighted average remaining contractual term	8 years 292 days	9 years 270 days
End of Period [Member]
Note 11 - Summary of Stock Options (Details) - Summary of Option Activity Under All Plans [Line Items]
Options outstanding	363,413
Weighted average exercise price	$1.24
Weighted average remaining contractual term	9 years 116 days	8 years 292 days
Options outstanding	2,291,783	363,413
Weighted average exercise price	$1.02	$1.24
Weighted average remaining contractual term	9 years 116 days	8 years 292 days

Note_11_Summary_of_Stock_Optio4

Note 11 - Summary of Stock Options (Details) - Summary of Options Outstanding and Exercisable (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding (in Shares)	2,291,783
Weighted Average Exercise Price, Outstanding	$1.02
Weighted Average Remaining Contractual Term	9 years 116 days
Weighted Average Exercise Price, Execisable	$2.45
Number Exercisable (in Shares)	519,901
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower	$0.60
Number Outstanding (in Shares)	1,901,476
Weighted Average Exercise Price, Outstanding	$0.60
Weighted Average Remaining Contractual Term	9 years 233 days
Weighted Average Exercise Price, Execisable	$0.60
Number Exercisable (in Shares)	129,594
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower	$1.24
Number Outstanding (in Shares)	312,373
Weighted Average Exercise Price, Outstanding	$1.24
Weighted Average Remaining Contractual Term	7 years 328 days
Weighted Average Exercise Price, Execisable	$1.24
Number Exercisable (in Shares)	312,373
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower	$7
Range of Exercise Price, Upper	$9
Number Outstanding (in Shares)	58,603
Weighted Average Exercise Price, Outstanding	$8.64
Weighted Average Remaining Contractual Term	7 years 167 days
Weighted Average Exercise Price, Execisable	$8.64
Number Exercisable (in Shares)	58,603
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower	$12
Range of Exercise Price, Upper	$18.63
Number Outstanding (in Shares)	19,081
Weighted Average Exercise Price, Outstanding	$15.29
Weighted Average Remaining Contractual Term	6 years 197 days
Weighted Average Exercise Price, Execisable	$15.29
Number Exercisable (in Shares)	19,081
Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower	$37
Number Outstanding (in Shares)	250
Weighted Average Exercise Price, Outstanding	$37
Weighted Average Remaining Contractual Term	3 years 171 days
Weighted Average Exercise Price, Execisable	$37
Number Exercisable (in Shares)	250

Note_11_Summary_of_Stock_Optio5

Note 11 - Summary of Stock Options (Details) - Valuation Assumptions for Stock Options (Employee Stock Option [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Note 11 - Summary of Stock Options (Details) - Valuation Assumptions for Stock Options [Line Items]
Expected term (in years)	5 years	5 years
Average volatility	61.00%	68.00%
Risk-free interest rate	1.80%	0.84%
Dividend yield	0.00%	0.00%

Note_11_Summary_of_Stock_Optio6

Note 11 - Summary of Stock Options (Details) - Stock-based Compensation Expense Included in the Statement of Income (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share based compensation expense	$184,000	$87,000
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share based compensation expense	5,000
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share based compensation expense	$179,000	$87,000

Note_12_Income_Taxes_Details

Note 12 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 12 - Income Taxes (Details) [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$2,257,000	$1,642,000
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	14,487,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	14,475,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	189,000	162,000
Unrecognized Tax Benefits	97,000	83,000	83,000
Domestic Tax Authority [Member]
Note 12 - Income Taxes (Details) [Line Items]
Deferred Tax Assets, Tax Credit Carryforwards, Research	165,000
State and Local Jurisdiction [Member]
Note 12 - Income Taxes (Details) [Line Items]
Deferred Tax Assets, Tax Credit Carryforwards, Research	$159,000

Note_12_Income_Taxes_Details_P

Note 12 - Income Taxes (Details) - Provision for Income Taxes Computed at Federal Statutory Rate	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Provision for Income Taxes Computed at Federal Statutory Rate [Abstract]
Income tax provision (benefit) at statutory rate	-34.00%	-34.00%
State income taxes, net of federal benefit	-6.00%	-6.00%
Merger transaction costs	6.00%
Change in valuation allowance	37.00%	39.00%
Other	-3.00%	1.00%
Effective tax rate	0.00%	0.00%

Note_12_Income_Taxes_Details_S

Note 12 - Income Taxes (Details) - Significant Components of Deferred Tax Assets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss carryforwards	$5,770	$4,203
Capitalized start up costs	7,751	7,156
Research and development credits	189	162
Accruals and reserves	169	99
Total deferred tax assets	13,879	11,620
Deferred tax liabilities:
Depreciation and amortization	-13	-11
Valuation allowance	($13,866)	($11,609)

Note_12_Income_Taxes_Details_U

Note 12 - Income Taxes (Details) - Unrecognized Tax Benefit Roll Forward (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2012
Unrecognized Tax Benefit Roll Forward [Abstract]
Balance as of the beginning of the year	$83,000	$83,000
Additions based upon tax positions related to the current year	14,000
Balance as of the end of the year	$97,000	$83,000

Note_13_Related_Party_Transact1

Note 13 - Related Party Transactions (Details) (USD $)	1 Months Ended	0 Months Ended	12 Months Ended
	Sep. 23, 2014	Oct. 04, 2007	Dec. 31, 2014	Dec. 31, 2013
Note 13 - Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	11,305,567
Stellartech Research Corporation [Member]
Note 13 - Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)		300,000
Related Party Transaction, Amounts of Transaction			$484,000	$33,000

Note_14_Segments_and_Geographi2

Note 14 - Segments and Geographic Information (Details) - Revenue from Unaffiliated Customers by Geographic Area (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Note 14 - Segments and Geographic Information (Details) - Revenue from Unaffiliated Customers by Geographic Area [Line Items]
Revenues	$90	$152
HONG KONG
Note 14 - Segments and Geographic Information (Details) - Revenue from Unaffiliated Customers by Geographic Area [Line Items]
Revenues	43
JAPAN
Note 14 - Segments and Geographic Information (Details) - Revenue from Unaffiliated Customers by Geographic Area [Line Items]
Revenues	40	152
CANADA
Note 14 - Segments and Geographic Information (Details) - Revenue from Unaffiliated Customers by Geographic Area [Line Items]
Revenues	4
Other [Member]
Note 14 - Segments and Geographic Information (Details) - Revenue from Unaffiliated Customers by Geographic Area [Line Items]
Revenues	$3

Note_14_Segments_and_Geographi3

Note 14 - Segments and Geographic Information (Details) - Long-lived Assets by Geographic Area (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 14 - Segments and Geographic Information (Details) - Long-lived Assets by Geographic Area [Line Items]
Long-lived assets	$187	$128
UNITED STATES
Note 14 - Segments and Geographic Information (Details) - Long-lived Assets by Geographic Area [Line Items]
Long-lived assets	60	98
CANADA
Note 14 - Segments and Geographic Information (Details) - Long-lived Assets by Geographic Area [Line Items]
Long-lived assets	21	30
Europe [Member]
Note 14 - Segments and Geographic Information (Details) - Long-lived Assets by Geographic Area [Line Items]
Long-lived assets	$106

Note_15_Subsequent_Events_Deta

Note 15 - Subsequent Events (Details) (USD $)	Dec. 31, 2014	Sep. 23, 2014	Feb. 28, 2015
Note 15 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$0.53	$0.53
Subsequent Event [Member] | Second Tranche [Member] | September 2014 Term Loan [Member]
Note 15 - Subsequent Events (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$500,000
Subsequent Event [Member] | Third Tranche [Member] | September 2014 Term Loan [Member]
Note 15 - Subsequent Events (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$1,000,000
Subsequent Event [Member]
Note 15 - Subsequent Events (Details) [Line Items]
Percent of Outstanding Loan Amount			1.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$0.53

Note_15_Subsequent_Events_Deta1

Note 15 - Subsequent Events (Details) - Future Minimum Lease Payments (USD $)	Dec. 31, 2014	Jan. 31, 2015
In Thousands, unless otherwise specified
Note 15 - Subsequent Events (Details) - Future Minimum Lease Payments [Line Items]
2015	$31
Total minimum lease payments	31
Subsequent Event [Member]
Note 15 - Subsequent Events (Details) - Future Minimum Lease Payments [Line Items]
2015		199
2016		229
2017		58
Total minimum lease payments		$486